Parkland

Board of Managers

Agenda for the ***Board of Managers*** meeting of the Dallas County Hospital District is scheduled for ***Wednesday, January 29, 2025, at 12:50 PM (or immediately following HOMES meeting)*** at 5200 Harry Hines Blvd (WISH Building) Dallas, TX 75235, Conference Room 02-175. (If assistance is needed in locating the room, please see the Administration receptionist on the 4th floor, 04-131.) A quorum will be physically present at the location of the meeting. Videoconferencing access is also possible via Webex. That application is available at https://www.webex.com/downloads.html. Teleconferencing access is possible by calling +1-415-655-0001. Both virtual access forms require inputting (meeting number: 2310 385 1697; meeting password: 1234) to join the meeting. The ***Board of Managers*** reserves the right to exercise discretion and may convene in Executive Session as permitted by Texas Government Code §§551.071 (consultation with attorney), 551.072 (deliberations regarding real estate), 551.074 (personnel matters), 551.076 (deliberations regarding security devices or security audits), 551.078 and/or 551.0785 (deliberations by medical committee or by governmental body that administers a public insurance, health or retirement plan regarding individuals' medical or psychiatric records), 551.085 (deliberation by governing board of certain providers of health care services), 551.087 (deliberation regarding economic development negotiations), 551.088 (deliberation regarding test item); Texas Government Code §418.183 (deliberation of information under §§418.175 – 418.182 for purposes of disaster management or disaster planning); Texas Health & Safety Code §161.032 (medical committee or medical peer review committee records, information or reports; and/or medical committee or medical peer review committee proceedings under Tex. Health & Safety Code Chapter 161 and/or Tex. Occ. Code Chapters 151 and 160); and/or as otherwise authorized by law on any item listed below. The ***Board of Managers*** may consider any of the agenda items in open or executive session and may continue the meeting as necessary to accomplish the business at the time and place designated by the Chair to reconvene.

	PAGE	TIME (MIN)	PRESENTER(S)
I. Opening/Call to Order/Determine the Presence of a Quorum Present/Mission Statement/Opening Remarks ***Advance Wellness | Relieve Suffering | Develop and Educate*** **I CARE** **I**ntegrity **C**ompassion and Collaboration **A**ccountability **R**espect **E**quity The agenda has been developed by the Chief Governance Officer in consultation with the Board Chair and reviewed and affirmed by Counsel.			Chair
A. Invocation by Rev. Josue Padilla		5	
B. Public Comments Regarding Agenda Items *See public comment registration information and rules at https://www.parklandhospital.com/board-of-managers*			
II. Consent Agenda: Minutes			
A. Consideration and Appropriate Action Regarding Minutes 2024-12-11 Facilities Committee	*5*	1	Chair
B. Consideration and Appropriate Action Regarding Minutes 2024-12-17 Budget & Finance Committee	*10*		
C. Consideration and Appropriate Action Regarding Minutes 2024-12-18 Quality of Care & Patient Safety Committee	*18*		
D. Consideration and Appropriate Action Regarding Minutes 2024-12-18 Board of Managers	*23*		
III. Consent Agenda: Contracts			Chair
A. Consideration and Appropriate Action Regarding Contracts over $200,000 **(See Attached List of Contracts)**	*33*		

		PAGE	TIME (MIN)	PRESENTER(S)
IV.	**Consent Agenda: Capital Substitutions**			
	A. Consideration and Appropriate Action Regarding Capital Substitutions **(See Attached List of Capital Substitutions)**	*68*		
V.	**Consent Agenda: Other**			Chair
	A. Consideration and Appropriate Action Regarding Fiscal 8311-1-15 Supplemental Retirement Plan Investment Policy	*71*		
	B. Consideration and Appropriate Action Regarding 2025 Southwestern Medical District Budget	*84*		
	C. Consideration and Appropriate Action Regarding Investment Committee Appointments	*90*		
	D. Consideration and Appropriate Action Regarding the Delegation of Signature Authority for Certain Matters to Dr. Brett Moran	*92*		
	E. Consideration and Appropriate Action Regarding the revised 2025 Audit Plan	*94*		
VI.	**Consent Agenda: Medical Executive Committee Items**			
	A. Consideration and Appropriate Action Regarding Medical Executive Committee Resolution for Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers	*96*		Chair
VII.	**Reports Requiring Deliberation(s) and/or Possible Action**			
	A. Strategic Facilities Plan Vision Statement and Tradeoffs Exercise	*98*	60	Blue Cottage of Cannon Design
	B. CEO Update on System Operations and Board FY25Q1 Priorities Discussion	*112*	20	Fred Cerise, MD
	C. Discussion Regarding Pension Funding Plan Recommendation	*132*	20	Rick Humphrey
	D. Consideration and Appropriate Action Regarding Fiscal 8311-1-14 Retirement Plan Investment Policy	*133*	5	Rick Humphrey
VIII.	**Break**			Chair
IX.	**Executive Session**			
	A. Discussion regarding Enterprise Risk Management *Tex. Gov't Code § 418.183(f).*	*182*	40	Fred Cerise, MD
	B. Update and Report Regarding Parkland's Cybersecurity Ongoing Initiatives *Tex. Gov't Code § 418.183(f).*	*183*	20	Joe Longo
X.	**Executive Session – Possible Deliberation**			
	A. Medical Executive Committee Credentialing Report *Tex. Health & Safety Code §161.032*	*213*		
XI.	**Reports Requiring Deliberation(s) and/or Possible Action**			

		PAGE	TIME (MIN)	PRESENTER(S)
A.	Possible Deliberation Regarding Supply Chain Sole Source Annual Report FY2024	*245*	5	Chair
B.	Possible Deliberation Regarding Supply Chain Annual Report FY2024	*246*		
C.	Possible Deliberation Regarding Report on Federal and State Grants with Awards of $200,000 or Greater	*247*		
XII.	**Action Items**			
A.	Board May Take Action on Any Agenda Item(s) Above			Chair
B.	Election of Officers of Parkland Health Board of Managers			
XIII.	**Adjourn**			Chair
A.	Closing Remarks			
B.	Call to Adjourn			

Invocation

Consideration and Appropriate Action Regarding Minutes 2024-12-11 Facilities Committee

Parkland

MINUTES

Dallas County Hospital District Board of Managers

Facilities Committee
December 11, 2024

Minutes of the Facilities Committee Development meeting of the Board of Managers of the Dallas County Hospital District, held Wednesday, December 11th, 2024, scheduled for 9:30 a.m. in the WISH Building Conference Room (02-175) at Parkland Health and via WebEx. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Vincent Hall noted that a quorum was physically present and called the meeting to order at 9:36 a.m. Committee member Reina Gonzalez, JD attended in-person and Farida Minner, RN joined via Webex. Marjorie Petty was appointed for quorum.

Staff Present (via Webex and in-person) included:

Beall Carothers, Director of Planning, Development & Construction
Donna Richardson, EVP Chief Nursing Executive
Edmundo Castañeda, EVP & Chief Operating Officer
Felicia Miller, EVP & Chief Talent Officer
Fred Cerise, Chief Executive Officer
Geoffrey Camp, VP Operations
Guy Toliver, Director Inclusion & Supplier Diversity
Jessica Hernandez, SVP & Chief DEI Officer
John Wilson, Director/PDC
James Clay Orrison, Administrative Resident
Lance Mendiola, VP Construction Facilities & Real Estate
Morgan Simmons, Governance Program Coordinator
Pamela Bryant, SVP & Chief Supply Chain Officer
Rick Humphrey, EVP Chief Financial Officer (via Webex)
Saul Cordero, VP & Chief Governance Officer
Steven Roth, EVP & Chief Legal Officer

II. Mission Statement

Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

V. Reports Requiring Deliberation(s) or Approval(s)

A. Facilities Minority and Women-Owned Business Enterprises (MWBE) Report

Guy Toliver provided the MWBE Report. He reported on MWBE participation percentages for Construction Contracts over $200,000 for all projects active in FY24. Next, he reported on MWBE participation percentages for Professional Services Contracts over $200K. Lastly, he presented MWBE participation percentages for Goods/Equipment Contracts over $200K.

The Committee asked questions and received further information related to the MWBE Report.

B. FY24 Projects

Lance Mendiola presented the FY24 Projects. He reviewed the projects and provided an update on the status of each.

- Former Parkland Campus Demolition
- Richland Clinic Replacement
- OK Paper Warehouse Demolition & Surface Parking
- Operating Room 6 Hybrid Endovascular Room at New Parkland Hospital
- Annie's Place (Child Care Services) Facilities Expansion
- Emergency Department Psych Intake
- Supply Chain Storeroom Expansion & Materials Resource Department Breakroom
- Flexible Sigmoidoscopy Room Buildout at New Parkland Hospital
- Acute Care Hospital 8th & 9th Floor Shell Buildout at New Parkland Hospital
- Interventional Radiology Expansion Project at New Parkland Hospital
- Emergency Department Triage Expansion at New Parkland Hospital
- Lab Consolidation at New Parkland Hospital
- Ambulatory Surgery Center Procedure Room Expansion
- Garland Community Oriented Primary Care Phase II Renovations
- Pharmacy Refill

Lance provided an in-depth presentation on a few of the FY24 projects. Lance began with an update on the Annie's Place Expansion construction which is 99% complete to date. Lance presented on the Former Parkland Demolition which is almost at completion with no building remanence left, topsoil added, and grass being planted. The topsoil and fill material are being placed to level the property with a final completion date of February 2025. Next Lance updated the Committee on the Richland/Vickery Clinic Replacement. The construction documents were finalized in October 2024 and the GMP was received November 13th. The current state of the project is estimated to exceed the construction budget by 10%. Lance presented on the OK Paper Warehouse Demolition & Surface Parking. The site is being prepared for the construction of 746 parking spaces. The City of Dallas Engineering permit is under the review process. Lance presented on the OR 6

Hybrid Endovascular Room which will contain additional imaging equipment for endovascular surgeries. Equipment will be brought in throughout the rest of December and int January. Next, Lance provided an update on the Psych Intake Expansion which has ongoing construction and will be substantially completed in February 2025. Lance presented on the 8th & 9th floor buildout which will result in 112 new Med Surg beds with anticipated schematic design completion in December 2024. Next, Lance provided an update on the Lab Consolidation project which will consolidate all Lab functions into the logistic building. Lastly, Lance provided an update on the Interventional Radiology Room 5 & 6 and the construction initiation in mid-2025.

C. Consideration and Appropriate Action Regarding the Garland Community Oriented Primary Care Phase II Renovations Contract

Vincent Hall prompted the Committee to discuss and consider the contract Regarding the Garland Community Oriented Primary Care Phase II Renovations Contract which will move to the Budget & Finance Committee and then the full Board upon recommendation from this meeting. Reina Gonzalez moved to recommend the contract. Marjorie Petty seconded the motion. The motion passed unanimously.

D. Consideration and Appropriate Action Regarding Modification #2 Pharmacy Refill Minor Interior Improvements Contract

Vincent Hall prompted the Committee to discuss and consider the contract regarding the Modification #2 Pharmacy Refill Minor Interior Improvements Contract which will move to the Budget & Finance Committee and then the full Board upon recommendation from this meeting. Reina Gonzalez moved to recommend the contract. Marjorie Petty seconded the motion. The motion passed unanimously.

E. Consideration and Appropriate Action Regarding Ambulatory Surgery Center Procedure Room Expansion Contract

Vincent Hall prompted the Committee to discuss and consider the contract regarding the Ambulatory Surgery Center Procedure Room Expansion Contract which will move to the Budget & Finance Committee and then the full Board upon recommendation from this meeting. Reina Gonzalez moved to recommend the contract. Marjorie Petty seconded the motion. The motion passed unanimously.

F. Consideration and Appropriate Action Regarding Deviation Request and Contract Modification for Parkland's Southeast Dallas Health Center Professional Building Lease Agreement Contract

Vincent Hall prompted the Committee to discuss and consider the contract regarding the Deviation Request and Contract Modification for Parkland's Southeast Dallas Health

Center Professional Building Lease Agreement Contract which will move to the Budget & Finance Committee and then the full Board upon recommendation from this meeting. Reina Gonzalez moved to recommend the contract. Marjorie Petty seconded the motion. The motion passed unanimously.

VI. Adjourn

With no further business to discuss, the Committee Chair adjourned the meeting at 10:02 a.m.

SO RECORDED:

_____	_____
Vincent Hall	Steven Roth, JD, MPH
Committee Chair	Assistant Secretary

Consideration and Appropriate Action Regarding Minutes 2024-12-17 Budget & Finance Committee

Parkland

MINUTES

Dallas County Hospital District Board of Managers

Budget and Finance
December 17, 2024

Minutes of the Budget and Finance Committee meeting of the Board of Managers of the Dallas County Hospital District, held Tuesday, December 17th , 2024, scheduled for 11:30 a.m. in the WISH Building Executive Conference Room (02-175) at Parkland Health and via WebEx. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Ramon Miguez, PE, noted that a quorum was physically present and called the meeting to order at 11:32 a.m. Committee members Byron Cryer, MD and Eric G. Bing attended in-person.

Board Member attendees included: Vincent Hall and Marjorie Petty.

Staff Present (via Webex and in-person) included:

Donna Richardson, EVP & CNE
Edmundo Castaneda, EVP & COO
Felicia Miller, EVP & Chief Talent Officer
Fred Cerise, President & Chief Executive Officer
Guy Toliver, Dir. Inclusion-Supply Diversity
Gerry Baker, Sr. VP Revenue Cycle
James Orrison, Administrative Resident
Jessica Hernandez, SVP & Chief DEI Officer
Keri Disney-Story, VP/Clinical Finance
Morgan Simmons, Governance Program Coordinator
Melanie Roberts, SVP/Chief Compliance & Ethics Officer
Pam Bryant, SVP Chief Supply Chain Officer
Rick Humphrey, EVP & Chief Financial Officer
Saul Cordero, SVP & Chief Governance & Strategy Officer
Steven Roth, EVP & Chief Legal Officer
Tabitha Lee, VP Finance
Vic Summers, SVP Internal Audit

II. Mission Statement

Committee Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

V. Reports Requiring Deliberation(s) or Approval(s)

A. Consideration and Appropriate Action Regarding Contracts over $200,000

Pam Bryant reviewed the briefing documents for contracts over $200,000. (See Appendix A of these minutes for more specific details on each contract). Pam Bryant presented each contract based on expense, capital, revenue, and selection method (sole source and non-sole source).

The Committee asked questions and received additional information related to the consideration of the contracts over $200,000.

Ramon Miguez asked for a motion to approve contracts over $200,000. Byron Cryer motioned for approval. Eric Bing seconded. The motion carried unanimously.

B. Consideration and Appropriate Action Regarding Fiscal 8311-1-15 Supplemental Savings Plan Investment Policy

Rick introduced this policy regarding the supplemental savings retirement planning. Rick mentioned there is a 457, 453 and 403b plans. This policy was last approved in January 2024 and there are minimal changes to the policy this year. The changes included: A change to the document name to "Supplemental Savings Plan Investment Policy", removal of the Investment Structure illustration, updated the name of the Investment Consultant and replaced the former consultants' illustration with the new consultants' illustration.

Ramon Miguez asked for a motion to approve the Supplemental Savings Policy. Byron Cryer motioned for approval. Eric Bing seconded. The motion carried unanimously.

C. Update and Report Parkland Financial Performance Presentation

For the month of November, Parkland Health recognized a net income of $10.2M which is $1.5M higher than the budgeted net income of $8.7M and $5.1M unfavorable compared to the prior year net income of $15.3M.

Parkland Health's operating margin and operating cash flow margin for the month of November are 0.3% and 3.6%, respectively. The operating margin was unfavorable compared to budget of 0.4% and the operating cash flow margin is unfavorable compared to budget of 3.9%. Parkland Health's operating margin is unfavorable compared to prior year operating margin of 0.6 and unfavorable to the operating cash flow margin of 4.0% from the prior year.

Parkland Health's patient cash collections in November were $91.2M which is higher than budget by $14.2M and $8.9M below the prior year. Parkland Health's days cash on hand of 171.5 days for the month is a decrease of 15.7 days compared to prior month of 187.2 days and compared to the prior year November of 171.1 days, an increase of 0.4 days.

Rick discussed the November month-to-date Key Statistics which showed variances positive to the overall budget. Rick mentioned although the variance was positive, there is a worsening payer mix and lower total cash flow by about one percent. Rick mentioned a raise in rates from about 3.8% from the beginning of November to 4.5% by end of November. Rick discussed the Parkland Health Plan which caused a $1.5 million decrease in operating margin.

Rick mentioned although October was positive across the board and November was much less favorable, the past two months evened out overall. The average length of stay goal is going to be 5.85 and so far, both October and November have met that target. The case mix for the month of November was strong along with patient cash which is above budget.

The Committee asked questions and received further information related to the Income Statements.

VI. Follow-Up Requests: None

VII. Closing Remarks

VIII. **Adjourn**

With no further business to discuss, Committee Chair Ramon Miguez, PE, adjourned the meeting at 12:54 pm.

SO RECORDED:

Ramon Miguez, PE Committee Chair	Steven Roth, JD, MPH Assistant Secretary

Appendix A (Contracts Reviewed for Appropiate Action)

Item	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.	MWBE %	MWBE Gender	MWBE Ethnicity
												December 18, 2024
					Medical Products and Services							
M1	Expense	Mod # 5 Watchman FLX Pro Left Atrial Appendage Closure Device	Boston Scientific	4/1/2019 - 4/30/2027	$700,000	$1,380,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Cheston Chan, Perioperative Services	0%	N/A	N/A
M2	Expense	Mod # 1 Cochlear Implants	Cochlear Americas	8/1/2022 - 7/31/2025	$180,000	$420,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Cheston Chan, Operating Room	0%	N/A	N/A
M3	Expense	Mod # 4 3M (Federal APD) Parking Services	Designa Access Corporation	3/1/2013 - 2/28/2030	$850,000	$1,991,312	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Marlin Suell, Police Department	0%	N/A	N/A
M4	Expense	Mod # 10 Data initiative	Dallas Fort Worth Hospital Council Ventures, Inc. (DFWHC)	1/1/2013 - 12/31/2027	$625,000	$3,111,737	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Vasu Polineni, Strategy & Business Development	0%	N/A	N/A
M5	Expense	Mod # 1 GE Diagnostic Imaging Systems Support & Maintenance	GE Precision Healthcare LLC	9/1/2023 - 8/31/2028	$375,000	$2,791,380	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year	Travis Kobernick, Clinical Engineering	0%	N/A	N/A
M6	Expense	Mod # 1 Amendment for one year extension	Hologic, Inc	1/29/2020 - 1/28/2026	$500,000	$2,665,112	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Sara Blacketer/Scott Hampton, Anatomic Pathology/Laboratory Services	0%	N/A	N/A
M7	Expense	Genesis Bi-wing Positioners	Infinitus Medical Technologies	12/19/2024 – 11/30/2029	$750,000	$750,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year	Cheston Chan, Perioperative Services	0%	N/A	N/A
M8	Revenue	Mod # 2 Resident Reimbursement	Tarrant County Hospital District d/b/a JPS Health System	7/1/2019 - 12/31/2024	($175,000)	($2,450,000)	Revenue	N/A-Revenue	Elizabeth Ponce, Graduate Medical Education	N/A	N/A	N/A
M9	Revenue	Resident Reimbursement	Tarrant County Hospital District d/b/a JPS Health System	1/1/2025 – 12/31/2025	($450,000)	($450,000)	N/A-Revenue	N/A-Revenue	Elizabeth Ponce, Graduate Medical Education	N/A	N/A	N/A

Parkland

MINUTES
Dallas County Hospital District Board of Managers

Budget and Finance
December 17, 2024

M10	Expense	Mod # 1 Extend current agreement three years and add funding	KLS Martin	11/1/2011 - 1/31/2028	$4,000,000	$7,840,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Cheston Chan, Perioperative Services	0%	N/A	N/A
M11	Expense	Valet Parking Service	Lanier Shuttle & Valet, Inc	1/1/2025 – 12/31/2029	$4,547,022	$4,547,022	Request for Proposals (Best Value)	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Kristi Tillery, Valet Parking Service	0%	N/A	N/A
M12	Expense	Mod # 9 Neuro Interventional Products	Medtronic USA, Inc	10/24/2018 - 12/31/2025	$435,000	$2,235,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	John Camacho, Interventional Radiology	0%	N/A	N/A
M13	Expense	MATC Software Evolution Support & Maintenance Services	Philips Healthcare	1/1/2025 – 12/31/2029	$6,745,676	$6,745,676	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Travis Kobernick, Clinical Engineering	0%	N/A	N/A
M14	Expense	Recycling and Shred Disposal Services	Republic Service, Inc	1/1/2025 – 12/31/2029	$736,118	$736,118	Request for Proposals (Best Value)	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Eric Walker, Operations Administration	0%	N/A	N/A
M15	Expense	Total Joint Products and Accessories	Smith & Nephew	Last Signature – 5 Years	$1,750,000	$1,750,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Perioperative Services	0%	N/A	N/A
M16	Expense	Mod # 1 Streck BCT Tubes Annual Quote Extension	Streck Laboratories	1/1/2024 - 12/31/2025	$246,000	$400,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Kristian Faulk/Scott Hampton, Laboratory Services/Chemistry	0%	N/A	N/A
M17	Expense	Mod # 4 Extend Umbilical Tags and Bands	Guard RFID Solutions, Inc	1/6/2016 - 1/15/2026	$45,000	$243,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Tamesha Pearson, WISH Administration	0%	N/A	N/A

M18	Expense	Tissue distribution contract	UTSW	1/1/2025 – 12/31/2029	$25,000,000	$25,000,000	Exempt from Competition	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Peri-op Services Department	N/A	N/A	N/A
M19	Expense	Water Treatment Services & Materials	Veolia WTS Services USA, Inc	1/1/2025 – 12/31/2029	$480,000	$480,000	Invitation for Bids	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Travis Kobernick, Clinical Engineering	0%	N/A	N/A
Construction and Facilities												
C1	Capital	Garland COPC Phase II Renovations	CMC Development & Construction	12/20/2024 – 7/19/2025	$500,000	$500,000	Invitation for Bids	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Asma Momin, Planning, Design and Construction	30.06%	See Chart	See Chart
C2	Capital	Mod # 2 Pharmacy Refill Minor Interior Improvements	Falkenberg Construction Co., Inc	1/29/2024 - 12/31/2024	$117,794	$533,937	Invitation for Bids	Yes, for the current fiscal year. Additional years costs will be	Paul Woodard, Planning Design and Construction	84%	See Chart	See Chart
C3	Capital	ASC Procedure Room Expansion	Swinerton Builders	12/20/2024 – 12/19/2025	$1,116,700	$1,116,700	Request for Qualifications	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Cynthia Harrington, Planning, Design and Construction	41.67%	TBD	TBD
C4	Capital	Lab Consolidation Custom Air Handler	Texas Air Systems	12/19/2024 – 11/30/2025	1060200	1060200	GPO Competition	Yes	Marc Leediker, Planning, Design and Construction	0%	N/A	N/A
C5	Capital	Lab Consolidation Pneumatic Tube Hardware	Translogic Corporation dba Swisslog Healthcare	Last Signature – 1 Year	$1,591,100	$1,591,100	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Marc Leediker, Planning, Design and Construction	0%	N/A	N/A
Information Technology												
IT1	Expense	Abridge Ambient Listening Solution	Abridge AI, Inc	12/20/2024 - 12/19/2027	$2,160,000	$2,160,000	Sole Source	Yes	Jeff DeFord / Joseph Longo, Information Technology	0%	N/A	N/A
IT2	Capital: New Parkland	Megahertz Technology, Inc	Leonardo DMR 800 MHz Radio System	Last signature – Five years	$3,244,190	$3,244,190	TXMAS or DIR Purchase	Yes	Longo, Information Technology	0%	N/A	N/A

Hospital Operations												
O1	Expense	Mod # 1 Add Funds	American Bottling Company	1/17/2017 - 2/27/2028	$735,911	$1,898,911	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year	Jeffrey Madison, Nutrition Services	0%	N/A	N/A
O2	Expense	Mod # 5 Recell Skin Grafting System	Avita Medical Americas LLC	7/26/2019 - 7/25/2027	$2,000,000	$4,560,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Cheston Chan, Operating Room	0%	N/A	N/A
O3	Revenue	Mod # 1 LMSW Services for DART Care	Dallas Area Rapid Transit	11/1/2023 - 10/31/2025	($622,709)	($1,183,019)	Contract Extension without Competition	N/A-Revenue	Kristin Peterson, Psych Social Work	0%	N/A	N/A
Ratification/Deviation/Informational Only												
D1	Revenue: Court Approval-Approved Deviation	Mod # 4 Amendment #6 to Lease Agreement	Michael Carroll M.D.	1/1/2013 - 12/31/2025	($27,119)	($436,937)	Sole Source Modification	N/A-Revenue	Beall Carothers, Planning Design & Construction	N/A	N/A	N/A
I1	Expense	2025 DART Employee Annual Pass	Dallas Area Rapid Transit (DART)	1/1/2025 - 12/31/2025	$474,480	$474,480	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Tawana McCullough, Office of Talent Management/ Total Rewards	0%	N/A	N/A

Consideration and Appropriate Action Regarding Minutes 2024-12-18 Quality of Care & Patient Safety Committee

Parkland

MINUTES

Dallas County Hospital District Board of Managers

Quality of Care and Patient Safety
December 18th, 2024

Minutes of the Quality of Care and Patient Safety Committee meeting of the Board of Managers of the Dallas County Hospital District, held Wednesday, December 18th, 2024, scheduled for 10:00 a.m. in the WISH Building Conference Room (02-175) at Parkland Health and via WebEx. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Committee Chair Elizabeth Palacios, MD, noted that a quorum was physically present and called the meeting to order at 10:00 am. Committee members Farida Minner, RN; Todd Furniss, JD and Eric G. Bing, MD attended in-person.

Board Member attendees included: Board Chair Marjorie Petty, JD, Reina Gonzalez, JD, Byron Cryer, MD; Ramon Miguez, PE, and Vincent Hall.

Staff Present (via Webex and in-person) included:

Brett Moran, ACMO-CMIO
Carmen Bowling, Interim SVP Nursing
David Alexander, SVP Nursing
Dawn Marchetto, SVP Nursing
Donna Richardson, EVP & CNE
Edmundo Castañeda, EVP & Chief Operating Officer
Fred Cerise, President & CEO
Gretchen Blake, VP Quality & Clinical Effectiveness
James Griffin, President of the Medical Executive Committee
James Orrison, Administrative Resident
Joseph Chang, SVP & CMO
Karen Garvey, VP Safety & Clinical Risk Management
Kathleen Doherty, VP Nursing Surgical Services
Lance Mendiola, Interim VP Construction/Real Estate
Michael Lane, SVP Chief Quality Safety Officer
Melanie Roberts, SVP/Chief Compliance & Ethics Officer
Morgan Simmons, Governance Program Coordinator
Sobha Fuller, SVP Nursing
Vic Summers, SVP Internal Audit

Attendees via Webex:

Marlin Suell, MBA, TCOLE, MPO – Chief, Dallas County Hospital District Police
Omaira Azizad, MD – Asc., Chief Quality & Safety Officer & Anesthesia
Barry Lewis-Harris, MD – Medical Director, Correctional Health
Pooja Koolwal, MD – Medical Director, Peritoneal Dialysis
Denise Harrington, LMSW, MBA, MHSM – Director of Programs, Transplant Services

II. Mission Statement

Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

IV. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

V. Executive Session – Quality & Patient Safety Operations Section

At 10:00 a.m. the Committee moved into Executive Session as permitted by the closed meeting exceptions specified on the agenda.

Members of management were excused from the discussion of topics, as necessary.

In executive session, the Committee received the presentation and reports as specified in the posted agenda.

A. Update and Report by Chief Quality and Safety Officer
Includes briefing from Executive Quality Committee (EQC)

B. Review of Safety Event Cause Analysis (CA) Case(s)
Shared learnings from recent safety event(s) with associated guide

C. Update and Report Regarding Safety Center, Serious Safety Events, and Cause Analysis Reporting
Annual report on activities and trends reported through Safety Center

D. Update and Report Regarding Quality-Related Key Performance Indicators (KPIs)
Reports for quality improvement project(s) throughout the enterprise

1. Department Performance Improvement Committee (PIC)/ Clinical Quality Committee (CQC) Annual Presentation(s)
   Annual report from service lines related to quality and safety
   a. Correctional Health PIC
   b. Peritoneal Dialysis PIC

E. Update and Report Regarding Hospital at Home Program
Annual Report for Program

F. Possible Deliberation Regarding the Following

A. Executive Summaries
Overview of QSO departmental reports

B. Quality of Care Dashboard
Monthly update of quality key performance indicators (KPIs)

C. Cause Analysis (CA) Log
List of upcoming cause analysis case reviews

D. Cause Analysis Supplemental
Additional cause analysis information

E. Texas Department of State Health Services (DSHS) Preventable Adverse Events (PAEs) Update
List of events

F. Nurse Staffing Effectiveness Committee Annual Report
Year-end report for FY2024 nursing staffing use and efficiency

G. Hospital at Home Supplemental Information
Additional information for Hospital at Home program

VI. Executive Session: Medical Executive Committee ("MEC")

James D. Griffin, MD, President of the Medical Executive Committee, discussed the items posted on the agenda starting at 11:42 am.

A. Consideration and Appropriate Action Regarding Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers

1. Medical Staff and Non-Physician Clinical Providers to Parkland Health
    a. Credentialing Report
    b. Delineation of Privileges (DoPs)
        i. Cardiovascular Medicine DoP – Triage to add CT and CTA

The Board asked questions and received additional information.

VII. Executive Session: Discussion regarding report and/or information provided by the Chief Quality Safety Officer and related items on this agenda.

The Committee conducted a discussion with the CQSO, Dr. Mike Lane without other members of management present.

VIII. **Executive Session: Discussion regarding report and/or information provided by the Medical Executive Committee President and related items on this agenda.**
The Committee conducted a discussion with the Medical Executive Committee President, Dr. James Griffin without other members of management present.

Chair adjourned Executive Session and moved into Open Session at 12:12 pm.

IX. **Action Items (Open Session)**

A. Consideration and Appropriate Action Regarding Medical Executive Committee Resolution for Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers

i. Approval of the Credentialing Report
ii. Approval of DoPs
1. Cardiovascular Medicine DoP – Triage and add CT to CTA

Todd Furniss motioned to approve the Executive Committee Recommendations and Delineation of Privileges. Eric Bing seconded the motion. The motion passed unanimously.

X. Follow-Up Requests: None

XI. Closing Remarks

XII. **Adjourn**
With no further business to discuss, Committee Chair Elizabeth Palacios, MD, adjourned the meeting at 12:12 pm.

SO RECORDED:

Elizabeth Palacios, MD	Steven Roth, JD, MPH
Committee Chair	Assistant Secretary

Consideration and Appropriate Action Regarding Minutes 2024-12-18 Board of Managers

Minutes of the Board of Managers meeting of the Dallas County Hospital District, held Wednesday, December 18th, 2024, scheduled for 12:50 PM. (or immediately following the HOMES meeting) in the WISH Building Conference Room (02-175) at Parkland Health and via WebEx. These minutes do not constitute a certified agenda from the meeting.

I. Attendance and Call to Order

Chair Marjorie Petty, JD, noted that a quorum was physically present and called the meeting to order at 1:10PM.

Board Member attendees included: Vincent Hall, Lisa Sutter (via Webex), Todd Furniss, JD, Eric G. Bing, MD, Farida Minner, RN, Byron Cryer MD, Reina Gonzalez, JD, Ramon Miguez, PE and Elizabeth palacios, MD.

Board member John Proctor was not present.

Staff Present (via Webex and in-person) included:
Donna Richardson, EVP & CNE
Edmundo Castañeda, EVP & Chief Operating Officer
Edna Ruano, Public Policy Advisor (Webex)
Fred Cerise, President & Chief Executive Officer
Felicia Miller, EVP & Chief Talent Officer
James Orrison, Administrative Resident
Joseph Chang, SVP & CMO
Jessica Hernandez, SVP & Chief DEI Officer
Joe Longo, Chief Information Officer
Joe Mayer, Director/Treasury
Guy Toliver, Dir., Inclusion-Supply Diversity
Keri Disney-Story, VP/Clinical Finance
Lance Mendiola, Interim VP Facilities
Morgan Simmons, Governance Program Coordinator
Melanie Roberts, SVP/Chief Compliance & Ethics Officer
Michael Lane, SVP Chief Quality and Safety Officer
Pamela Bryant, SVP/Supply Chain Management
Rick Humphrey, EVP & Chief Financial Officer
Saul Cordero, SVP & Chief Governance & Strategy Officer
Steven Roth, EVP & Chief Legal Office
Stephanie Crank, RN Prof Development Practitioner
Vic Summers, SVP Internal Audit

Additional Attendees:
Socorro Salazar, Dallas County Commission (via Webex)
JD Davis – Milliman
Leo Festino and Aaron Lally – Meketa
Kristen Harrison, The Smith Group (via Webex)

II. Mission Statement

The Chair began the meeting by stating the mission statement:
Advance Wellness | Relieve Suffering | Develop and Educate

III. Invocation

Rev. Dr. Geoffrey Moore offered an invocation at the beginning of the meeting.

IV. Public Comments Regarding Non-Agenda Items

No members of the public registered for comments regarding the non-agenda items

V. Public Comments Regarding Agenda Items

No members of the public registered for comments regarding the agenda items.

VI. Conflicts of Interest

After review of the agenda, the Chair noted zero conflicts of interest for Board Members present.

VII. Consent Agenda: Minutes

A. Consideration and Appropriate Action Regarding Minutes 2024-11-06 Governance, Compliance and Ethics Committee

B. Consideration and Appropriate Action Regarding Minutes 2024-11-06 Talent Development and

C. Executive Compensation Committee

D. Consideration and Appropriate Action Regarding Minutes 2024-11-13 Audit Committee

E. Consideration and Appropriate Action Regarding Minutes 2024-11-13 Facilities Committee

F. Consideration and Appropriate Action Regarding Minutes 2024-11-19 Budget & Finance Committee

G. Consideration and Appropriate Action Regarding Minutes 2024-11-20 Quality of Care & Patient Safety Committee

H. Consideration and Appropriate Action Regarding Minutes 2024-11-20 Board of Managers

I. Consideration and Appropriate Action Regarding Minutes 2024-11-20 Board of Managers – Strategic Facilities Planning Session

VIII. Consent Agenda: Contracts

Consideration and Appropriate Action Regarding Contracts over $200,000 **(See Attached List of Contracts)**

IX. Consent Agenda: Policies

Consideration and Appropriate Action Regarding 8311-1-04, Investment Policy - Operating Funds

X. Consent Agenda: Other

Consideration and appropriate Action Regarding the 2025 Audit Plan

Marjorie Petty asked for a motion to approve the consent agenda. Todd Furniss motioned for approval. Elizabeth Palacios seconded. The motion carried unanimously.

XI. Reports Requiring Deliberation(s) or Approval(s)

A. Update and Report by Chief Executive Officer Regarding Strategic and Operational Performance and Plans

Dr. Cerise presented on the Butler property between Parkland and Dallas College. There is a letter of intent in place for this property. Dr. Cerise mentioned the steps for the purchase agreement and the 90-day feasibility period to go along with in are processing now. Dr. Cerise mentioned the implementation of food services and childcare development programs into the Dallas College agreement as well. Dr. Cerise mentioned the position split of the Chief Medical Officer and now a Chief Health Officer which will oversee the delivery of care, systemic improvements, research innovation and digital health.

The Board asked further questions and received additional information about the topics discussed during the Chief Executive Officer Update.

B. Presentation on Parkland Pension Plan Funding

JD Davis from Milliman presented on the Parkland Pension Plan Funding. JD refreshed the Board on the overall goal of this presentation which was to remind them of the funded status of the retirement plan terms, to discuss a potential one-time additional cash infusion in early 2025 and project the impact that will have on the plans funded status. JD discussed the progression of assets and liability in the plan Parkland currently uses. JD next reviewed the plan funding history from 2012 through 2024. JD next discussed the funding projections for the next 10 years. JD mentioned the long-term goal is to get the plan at or near 100% funded. JD explained the projection of the determined contribution is going to be somewhere in the $85 to $90 million range. Parkland may choose to make a one-time contribution in early 2025 and depending on the magnitude of that contribution Parkland's investment and price range may vary. Next, JD explained the importance of future assets and Parkland's pension plan which is comprised of employer contributions, employee contributions and investment return. A higher rate of asset return achieved over time will reduce contributions otherwise required.

C. Presentation on Private Equity and Credit

Leo Festino provided a comprehensive overview of the benefits and considerations of incorporating private equity and private credit into Parkland's investment portfolio. Leo discussed the background on this matter in chronological order with the Investment Committee conducting an open and competitive bidding process back in 2023 to partner with an investment advisory firm that has experience in both public and private markets. In 2024, the investment committee evaluated the pension plan's asset allocation and educated the Parkland Board on private equity and debt. In September 2024 the Investment Committee further evaluated new asset allocation policies and favored a desired mix with a 5% target exposure to private equity and debt. Leo reminded the Board that these asset classes are now common among peers and public hospital systems are not considered outliers. Leo reviewed the pros and cons of private equity and debt with the Board and reviewed the average private equity allocation strategies of organizations with similar scopes. The Investment Committee supports adding illiquid assets to the portfolio, with a proposed combination of liquid equity and illiquid debt strategies. The target approach is to start small and gradually increase exposure over time. Aaron Lally discussed the specific pros and cons of private debt and reviewed the recommended allocation strategy for this asset. Next, Leo ended the presentation with the expected impact on return and volatility for Parkland over 20 years.

The Board asked follow-up questions and received additional material regarding the presentation of private equity and credit.

Scheduled 5 Minute Break

XII. Executive Session

At 2:58 pm., the Board went into Executive Session as permitted by the closed meeting exceptions specified on the agenda.

Members of management were excused from the discussion of topics, as necessary.

A. Discussion Regarding the Joint Commission Survey and Findings
Tex. Health & Safety Code §161.032 & §161.0315 and Tex. Occupations Code §160.007

B. Report Regarding Patient Outcome Based on Efficacy of the Digital Health Surveillance System
Tex. Health & Safety Code §161.032.

C. Presentation on Legal Review of Parkland Procurement Procedures
Tex. Gov't Code § 551.071

D. Legal Update on Business Diversity Programs, Presentation on Legal Review of Parkland Minority & Women Owned Business Enterprise (MWBE) Program Review and Availability Study
Tex. Gov't Code § 551.071

E. Update and Report Regarding Parkland's Cybersecurity Ongoing Initiatives
Tex. Gov't Code § 418.183(f)

Chair adjourned Executive Session and moved into Open Session at 4:41 pm.

XIII. Adjourn

With no further business to discuss, the Chair adjourned the meeting at 4:49 p.m.

SO RECORDED:

Marjorie D. Petty, JD	Steven Roth, JD, MPH
Chair	Assistant Secretary

Parkland

MINUTES
Dallas County Hospital District Board of Managers

Board
December 18th, 2024

Appendix A (Contracts Reviewed for Appropiate Action)

Item	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.	MWBE %	MWBE Gender	MWBE Ethnicity
December 18, 2024												
Medical Products and Services												
M1	Expense	Mod # 5 Watchman FLX Pro Left Atrial Appendage Closure Device	Boston Scientific	4/1/2019 - 4/30/2027	$700,000	$1,380,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Cheston Chan, Perioperative Services	0%	N/A	N/A
M2	Expense	Mod # 1 Cochlear Implants	Cochlear Americas	8/1/2022 - 7/31/2025	$180,000	$420,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Cheston Chan, Operating Room	0%	N/A	N/A
M3	Expense	Mod # 4 3M (Federal APD) Parking Services	Designa Access Corporation	3/1/2013 - 2/28/2030	$850,000	$1,991,312	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Marlin Suell, Police Department	0%	N/A	N/A
M4	Expense	Mod # 10 Data initiative	Dallas Fort Worth Hospital Council Ventures, Inc. (DFWHC)	1/1/2013 - 12/31/2027	$625,000	$3,111,737	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Vasu Polineni, Strategy & Business Development	0%	N/A	N/A
M5	Expense	Mod # 1 GE Diagnostic Imaging Systems Support & Maintenance	GE Precision Healthcare LLC	9/1/2023 - 8/31/2028	$375,000	$2,791,380	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year	Travis Kobernick, Clinical Engineering	0%	N/A	N/A
M6	Expense	Mod # 1 Amendment for one year extension	Hologic, Inc	1/29/2020 - 1/28/2026	$500,000	$2,665,112	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Sara Blacketer/Scott Hampton, Anatomic Pathology/Laboratory Services	0%	N/A	N/A
M7	Expense	Genesis Bi-wing Positioners	Infinitus Medical Technologies	12/19/2024 – 11/30/2029	$750,000	$750,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year	Cheston Chan, Perioperative Services	0%	N/A	N/A
M8	Revenue	Mod # 2 Resident Reimbursement	Tarrant County Hospital District d/b/a JPS Health System	7/1/2019 - 12/31/2024	($175,000)	($2,450,000)	Revenue	N/A-Revenue	Elizabeth Ponce, Graduate Medical Education	N/A	N/A	N/A
M9	Revenue	Resident Reimbursement	Tarrant County Hospital District d/b/a JPS Health System	1/1/2025 – 12/31/2025	($450,000)	($450,000)	N/A-Revenue	N/A-Revenue	Elizabeth Ponce, Graduate Medical Education	N/A	N/A	N/A

M10	Expense	Mod # 1 Extend current agreement three years and add funding	KLS Martin	11/1/2011 - 1/31/2028	$4,000,000	$7,840,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Cheston Chan, Perioperative Services	0%	N/A	N/A
M11	Expense	Valet Parking Service	Lanier Shuttle & Valet, Inc	1/1/2025 – 12/31/2029	$4,547,022	$4,547,022	Request for Proposals (Best Value)	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Kristi Tillery, Valet Parking Service	0%	N/A	N/A
M12	Expense	Mod # 9 Neuro Interventional Products	Medtronic USA, Inc	10/24/2018 - 12/31/2025	$435,000	$2,235,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	John Camacho, Interventional Radiology	0%	N/A	N/A
M13	Expense	MATC Software Evolution Support & Maintenance Services	Philips Healthcare	1/1/2025 – 12/31/2029	$6,745,676	$6,745,676	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Travis Kobernick, Clinical Engineering	0%	N/A	N/A
M14	Expense	Recycling and Shred Disposal Services	Republic Service, Inc	1/1/2025 – 12/31/2029	$736,118	$736,118	Request for Proposals (Best Value)	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Eric Walker, Operations Administration	0%	N/A	N/A
M15	Expense	Total Joint Products and Accessories	Smith & Nephew	Last Signature – 5 Years	$1,750,000	$1,750,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Perioperative Services	0%	N/A	N/A
M16	Expense	Mod # 1 Streck BCT Tubes Annual Quote Extension	Streck Laboratories	1/1/2024 - 12/31/2025	$246,000	$400,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Kristian Faulk/Scott Hampton, Laboratory Services/Chemistry	0%	N/A	N/A
M17	Expense	Mod # 4 Extend Umbilical Tags and Bands	Guard RFID Solutions, Inc	1/6/2016 - 1/15/2026	$45,000	$243,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Tamesha Pearson, WISH Administration	0%	N/A	N/A

M18	Expense	Tissue distribution contract	UTSW	1/1/2025 – 12/31/2029	$25,000,000	$25,000,000	Exempt from Competition	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Peri-op Services Department	N/A	N/A	N/A
M19	Expense	Water Treatment Services & Materials	Veolia WTS Services USA, Inc	1/1/2025 – 12/31/2029	$480,000	$480,000	Invitation for Bids	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Travis Kobernick, Clinical Engineering	0%	N/A	N/A
Construction and Facilities												
C1	Capital	Garland COPC Phase II Renovations	CMC Development & Construction	12/20/2024 – 7/19/2025	$500,000	$500,000	Invitation for Bids	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Asma Momin, Planning, Design and Construction	30.06%	See Chart	See Chart
C2	Capital	Mod # 2 Pharmacy Refill Minor Interior Improvements	Falkenberg Construction Co., Inc	1/29/2024 - 12/31/2024	$117,794	$533,937	Invitation for Bids	Yes, for the current fiscal year. Additional years costs will be	Paul Woodard, Planning Design and Construction	84%	See Chart	See Chart
C3	Capital	ASC Procedure Room Expansion	Swinerton Builders	12/20/2024 – 12/19/2025	$1,116,700	$1,116,700	Request for Qualifications	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Cynthia Harrington, Planning, Design and Construction	41.67%	TBD	TBD
C4	Capital	Lab Consolidation Custom Air Handler	Texas Air Systems	12/19/2024 – 11/30/2025	1060200	1060200	GPO Competition	Yes	Marc Leediker, Planning, Design and Construction	0%	N/A	N/A
C5	Capital	Lab Consolidation Pneumatic Tube Hardware	Translogic Corporation dba Swisslog Healthcare	Last Signature – 1 Year	$1,591,100	$1,591,100	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Marc Leediker, Planning, Design and Construction	0%	N/A	N/A
Information Technology												
IT1	Expense	Abridge Ambient Listening Solution	Abridge AI, Inc	12/20/2024 - 12/19/2027	$2,160,000	$2,160,000	Sole Source	Yes	Jeff DeFord / Joseph Longo, Information Technology	0%	N/A	N/A
IT2	Capital: New Parkland	Megahertz Technology, Inc	Leonardo DMR 800 MHz Radio System	Last signature – Five years	$3,244,190	$3,244,190	TXMAS or DIR Purchase	Yes	Longo, Information Technology	0%	N/A	N/A

Hospital Operations												
O1	Expense	Mod # 1 Add Funds	American Bottling Company	1/17/2017 - 2/27/2028	$735,911	$1,898,911	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year	Jeffrey Madison, Nutrition Services	0%	N/A	N/A
O2	Expense	Mod # 5 Recell Skin Grafting System	Avita Medical Americas LLC	7/26/2019 - 7/25/2027	$2,000,000	$4,560,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Cheston Chan, Operating Room	0%	N/A	N/A
O3	Revenue	Mod # 1 LMSW Services for DART Care	Dallas Area Rapid Transit	11/1/2023 - 10/31/2025	($622,709)	($1,183,019)	Contract Extension without Competition	N/A-Revenue	Kristin Peterson, Psych Social Work	0%	N/A	N/A
Ratification/Deviation/Informational Only												
D1	Revenue: Court Approval-Approved Deviation	Mod # 4 Amendment #6 to Lease Agreement	Michael Carroll M.D.	1/1/2013 - 12/31/2025	($27,119)	($436,937)	Sole Source Modification	N/A-Revenue	Beall Carothers, Planning Design & Construction	N/A	N/A	N/A
I1	Expense	2025 DART Employee Annual Pass	Dallas Area Rapid Transit (DART)	1/1/2025 - 12/31/2025	$474,480	$474,480	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets	Tawana McCullough, Office of Talent Management/ Total Rewards	0%	N/A	N/A

Consideration and Appropriate Action Regarding Contracts over $200,000

Item	Contract Type	Service or Product	Supplier	Contract Term	Current Contract Approval Amount Request	New Approved Contract Value	Selection Method	Budgeted?	Business Owner / Dept.	MWBE %	MWBE Gender	MWBE Ethnicity
												January 29, 2025
Medical Products and Services												
M1	Expense	Mod to Add Funds #3 Venaseal & ClosureFast Products	Medtronic USA, Inc.	10/30/2024 - 12/23/2025	$249,000	$700,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	John Camacho, Interventional Radiology	0%	N/A	N/A
M2	Expense	Mod to Add Funds 1 WALRUS balloon catheters	Q'Apel Medical, Inc.	3/2/2023 - 3/1/2026	$87,000	$212,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	John Camacho, Interventional Radiology	0%	N/A	N/A
M3	Expense	Mod # 5 Intravascular Lithotripsy ("IVL") Products	Shockwave Medical Inc.	10/25/2023 - 3/1/2027	$1,200,000	$2,148,000	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Perioperative Services	0%	N/A	N/A
M4	Expense	Mod # 7 Radial align, stems, and screws for orthopedic implants	Skeletal Dynamics	7/26/2023 - 1/31/2027	$1,400,000	$4,494,953	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Perioperative Services	0%	N/A	N/A
M5	Capital	Lifepack CR2 semi-automatic Automated External Defibrillators	Stryker Sales, LLC	Last Signature – 12/31/2025	$243,228	$243,228	GPO Purchase	Yes	Andrew Hohman, Clinical Engineering	0%	N/A	N/A
M6	Expense	Mod # 3 Blood apheresis disposables/consumables	Terumo BCT	10/25/2023 - 12/31/2025	$353,289	$2,172,710	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Tanisha Tatum, Apheresis Department	0%	N/A	N/A
M7	Expense	Angio-Seal Vessel Products	Terumo Medical	2/1/2025 – 1/31/2028	$1,625,000	$1,625,000	Sole Source	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Surgical Administration	0%	N/A	N/A
M8	Expense	Mod # 1 Extend Contract for two (2) years and add funding	Texas Practitioners LLC	2/22/2023 - 2/28/2027	$375,000	$1,100,319	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Cheston Chan, Peri-op Services	0%	N/A	N/A

M9	Expense	Mod # 1 Apheresis kits and sterile solution	Therakos	9/28/2024 - 1/31/2026	$386,627	$570,958	Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Tanisha Tatum, Apheresis Department	0%	N/A	N/A
Construction and Facilities												
C1	Capital	Construction Manager at Risk (CMAR) for Lab Consolidation	Swinerton Builders	2/1/2025 – 3/31/2026	$10,106,000	$10,106,000	Request for Qualifications	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Marc Leediker, Planning, Design and Construction	30%	TBD	TBD
C2	Expense: Court Approval	Declaration of Access and Drainage Agreement (Easement Agreement)	Parkland Health	1/1/2025 – no expiration date	$0	$0	Real Estate – Exemption	N/A-Zero Dollar	Lance Mendiola, Interim Vice President of Construction, Facilities, Real Estate, Operations Administration	0%	N/A	N/A
Information Technology												
IT1	Expense	VMware Customer Portfolio Manager (Support Services)	CA, Inc. a Broadcom Company	Last signature – Three years	$1,000,000	$1,000,000	Sole Source	Yes	Joseph Longo, Information Technology	0%	N/A	N/A
IT2	Expense	VMware Workspace One Mobile Essentials SaaS	Carahsoft Technology Corp.	12/27/2024 – 12/26/2027	$2,852,619	$2,852,619	Sole Source	Yes	Joseph Longo, Information Technology	0%	N/A	N/A
Hospital Operations												
O1	Expense	Mod # 1 Claim Scrubber and Eligibility RTE	Waystar, Inc.	6/27/2024 - 6/26/2027	$3,571,452	$6,249,329	Non-Sole Source Modification	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.	Gerry Baker, Patient Financial Services	0%	N/A	N/A

Board Approval Request For Modification to Contract or Funding

BOM Date: January 29, 2025	**Modification:** Mod to Add Funds #3 Venaseal & ClosureFast Products	
Business Owner: John Camacho	**Business Owner Dept:** Interventional Radiology	**Contract Number:** POCP-22172 A7
Vendor/Supplier: Medtronic USA, Inc. **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total (10/30/2024):	$427,000
	Actions Totaling < $100,000 Amount:	$24,000
Revenue, Expense or Capital: Expense	Modification that increases contract value to $100,000 more than BOM Approved Contract Total Mod to Add Funds # 3 Amount:	$249,000
Original Start Date: 10/30/2024 **Current Expiration:** 12/23/2025 **Mod Start Date:** 1/29/2025 **Expiration after this Mod:** 12/23/2025	New Contract Amount:	$700,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Jenni Burnes, Vice President, Ancillary Services, Operations Administration

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 3 Venaseal & ClosureFast Products

VENDOR: Medtronic USA, Inc.

COST:

BOM Approved Contract Total (10/30/2024):	$427,000
Action Amount:	$24,000
Modification # 3:	+ $249,000
Total:	$700,000

Recommendation
Approve this contract modification to Venaseal & ClosureFast Products.

Background
This contract is to purchase Venaseal & ClosureFast endovenous radiofrequency ablation (RFA) catheters. The catheters are used with the ClosureFast radiofrequency generator to collapse and close enlarged leg veins in patients with varicose veins and Chronic Venous Insufficiency (CVI). It is necessary to add funding due to increased usage above original estimates.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is 12% lower than the average for other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2025	FY2026	Total
$427,000	$250,250	$22,750	$700,000

Sole Source Justification
This contract is for a good or service for which there is only one acceptable source. The products/services are additions or modifications to existing systems or equipment where there are no substitute or interchangeable components, software, or maintenance sources and compatibility is paramount.

Document Contact/Author:	William Jones

Parkland

Board Approval Request For Modification to Contract or Funding

BOM Date: January 29, 2025	**Modification:** Mod to Add Funds 1 WALRUS balloon catheters	
Business Owner: John Camacho	**Business Owner Dept:** Interventional Radiology	**Contract Number:** POCP-22191 A1
Vendor/Supplier: Q'Apel Medical, Inc. **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	Current Contract Amount:	$125,000
Revenue, Expense or Capital: Expense	Modification # 1 Amount:	$87,000
Original Start Date: 3/2/2023 **Current Expiration:** 3/1/2026 **Mod Start Date:** 3/20/2025 **Expiration after this Mod:** 3/1/2026	New Contract Amount:	$212,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Jenni Burnes, Vice President, Ancillary Services, Operations Administration

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # 1 WALRUS balloon catheters

VENDOR: Q'Apel Medical, Inc.

COST:		
	Current Contract Amount:	$125,000
	Modification # 1:	+ $87,000
	Total:	$212,000

Recommendation
Approve this contract modification to WALRUS balloon catheters.

Background
This contract is to purchase Walrus balloon guide catheters. The catheters are used in Interventional Radiology procedures to aid the insertion and guidance of intravascular catheters into selected blood vessels in the brain, spine, or outside the heart. The catheters are also used as a conduit for clot retrieval devices. It is necessary to add funding due to increased usage above original estimates.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is in line with the average for other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2025	FY2026	Total
$125,000	$50,750	$36,250	$212,000

Sole Source Justification
This contract is for a good or service for which it is impractical to obtain competition. Implants, heart valves, bone screws, prosthetics, etc. are patient care devices and are exempt.

Document Contact/Author:	William Jones

Board Approval Request For Modification to Contract or Funding

BOM Date: January 29, 2025	**Modification:** Mod # 6 Intravascular Lithotripsy ("IVL") Products	
Business Owner: Cheston Chan	**Business Owner Dept:** Perioperative Services	**Contract Number:** POCP-21665 A6
Vendor/Supplier: Shockwave Medical Inc. **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total (10/25/2023):	$948,000
Revenue, Expense or Capital: Expense	Modification # 6 Amount:	$1,200,000
Original Start Date: 10/25/2023 **Current Expiration:** 3/1/2027 **Mod Start Date:** 9/25/2024 **Expiration after this Mod:** 3/1/2027	New Contract Amount:	$2,148,000

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Legal approved base document, amendment has no changes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): David Alexander, Senior Vice President, Nursing

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 6 Intravascular Lithotripsy (“IVL”) Products

VENDOR: Shockwave Medical Inc.

COST:

BOM Approved Contract Total (10/25/2023):	$948,000
Modification # 6:	+ $1,200,000
Total:	$2,148,000

Recommendation
Approve this contract modification to Intravascular Lithotripsy (“IVL”) Products.

Background
Intravascular lithotripsy is used to open narrowed or blocked arteries in the heart to allow efficient blood flow. This is accomplished through the introduction of a catheter into the blockage area and insertion of a stent. There is increased due to multiple interventional cardiologists are now assigned to Cath Lab and based on the patient clinical need.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is on average with other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2025	FY2026	FY2027	Total
$948,000	$433,333	$400,000	$366,667	$2,148,000

Sole Source Justification
This contract is for a good or service for which it is impractical to obtain competition. This is a process that is required to properly place an implant.

Document Contact/Author:	Bryson Hendrix

Board Approval Request For Modification to Contract or Funding

BOM Date: January 29, 2025	**Modification:** Mod # 7 Radial align, stems, and screws for orthopedic implants	
Business Owner: Cheston Chan	**Business Owner Dept:** Perioperative Services	**Contract Number:** POCP-18532 A7
Vendor/Supplier: Skeletal Dynamics **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total (7/26/2023):	$3,094,953
Revenue, Expense or Capital: Expense	Modification # 7 Amount:	$1,400,000
Original Start Date: 7/26/2023 **Current Expiration:** 1/31/2025 **Mod Start Date:** 2/1/2025 **Expiration after this Mod:** 1/31/2027	New Contract Amount:	$4,494,953

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): David Alexander, Senior Vice President, Nursing, Executive Nursing Leadership

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # 7 Radial align, stems, and screws for orthopedic implants

VENDOR: Skeletal Dynamics

COST:

BOM Approved Contract Total (7/26/2023):	$3,094,953
Modification # 7:	+ $1,400,000
Total:	$4,494,953

Recommendation
Approve this contract modification to Radial align, stems, and screws for orthopedic implants.

Background
This contract is for patient care devices/ implants (plates, screws) which are used in the operating room for surgical treatment of forearm (distal radius) trauma injuries.

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is 7% lower than the average for other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Current Contract Amount	FY2025	FY2026	FY2027	Total
$3,094,953	$583,333	$700,000	$116,667	$4,494,953

Sole Source Justification
This contract is for a good or service for which it is impractical to obtain competition. Implants, heart valves, bone screws, prosthetics, etc. are patient care devices and are exempt.

Document Contact/Author:	Bryson Hendrix

Parkland

Board Approval Request For Contracts Over $200,000

BOM Date: January 29, 2025	**Product or Service:** Lifepack CR2 semi-automatic Automated External Defibrillators	
Business Owner: Andrew Hohman	**Business Owner Dept:** Clinical Engineering	**Contract Number:** POCP-24913
Vendor/Supplier/Contractor: Stryker Sales, LLC	**Source Selection Methodology:** GPO Purchase	**Fair and Reasonable Price Determination:** Adequate Competition

Revenue, Expense or Capital:

Capital

	Contract Dates	Contract Price
Base Term:	Last Signature – 12/31/2025	$243,228
Out Years:	0 Year(s)	+$0
Total:	Last Signature – 12/31/2025	$243,228

Lowest Bidder

Is this contractor the lowest bidder/supplier? GPO Purchase

If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes

Does this contract have an IT Component? No

Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes

FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, and vendor does not have a corporate plan.

Were M/WBE's Directly Solicited? N/A-no solicitation performed

Number Responding M/WBE's: N/A-no solicitation performed

What % of this contract is M/WBE? 0%

M/WBE Race/Ethnicity? N/A

M/WBE Gender? N/A

Submitted By (Division VP): Lance Mendiola, Interim Vice President of Construction, Facilities Management and Real Estate

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Lifepack CR2 semi-automatic Automated External Defibrillators

VENDOR: Stryker Sales, LLC

COST:		
	Base Term:	$243,228
	Out Years:	+ $0
	Total:	$243,228

Recommendation
Approve this contract for Lifepack CR2 semi-automatic Automated External Defibrillators .

Background
This contract is for 118 Lifepack CR2 semi-automatic Automated External Defibrillator (AED) devices from Stryker. The Lifepack CR2 is a type of AED that allows chest compressions during electrocardiogram (ECG) rhythm analysis. This purchase will standard the entire fleet across the organization. i

Fair and Reasonable Price Determination
The GPO contract and pricing was obtained in a solicitation process performed by Vizient. Per a Vizient analysis, we are receiving the GPO contracted price and discount. Market research conducted through ECRI shows that the Parkland price is 8.7% lower than the average for other facilities for similar models (they have not seen any recent Capital Guide member interest in this specific model). ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Base Term	FY2025
Equipment / Licenses	$243,228

Document Contact/Author:	Andrew Barter

Board Approval Request For Modification to Contract or Funding

BOM Date: January 29, 2025	**Modification:** Mod # 3 Blood apheresis disposables/consumables	
Business Owner: Tanisha Tatum	**Business Owner Dept:** Apheresis Department	**Contract Number:** POCP-19843 A3
Vendor/Supplier: Terumo BCT **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total (10/25/2023)	$1,819,421
Revenue, Expense or Capital: Expense	Modification # 3 Amount:	$353,289
Original Start Date: 10/25/2023 **Current Expiration:** 1/31/2025 **Mod Start Date:** 2/1/2025 **Expiration after this Mod:** 12/31/2025	New Contract Amount:	$2,172,710

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Judy Herrington, Senior Vice President, Nursing

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # 3 Blood apheresis disposables/consumables

VENDOR: Terumo BCT

COST:

BOM Approved Contract Total (10/25/2023)	$1,819,421
Modification # 3:	+ $353,289
Total:	$2,172,710

Recommendation
Approve this contract modification to Blood apheresis disposables/consumables.

Background
Blood Apheresis is the removal of blood plasma from the body by the withdrawal of blood, its separation into plasma and cells, and the reintroduction of the cells, used especially to remove antibodies in treating autoimmune disease. The fleet currently totals 5 (five) Terumo BCT Apheresis Systems. This purchase is for the associated disposables/consumables and training needed to operate the Systems for another year.

Fair and Reasonable Price Determination
Prices were benchmarked using ECRI's benchmarking services. Some products are benchmarked lower than median price, and some above the 75th percentile. One of the products priced above the 75th percentile, is due to lower volume use.

Financial Forecast

Current Contract Amount	FY2025	Total
$1,819,421	$353,289	$2,172,710

Sole Source Justification
This contract is for a good or service for which there is only one acceptable source. The products/services are additions or modifications to a fleet of equipment awarded to a single vendor. These disposables/consumables are being bought to be used on our existing fleet.

Document Contact/Author:	Stephanie Toth

Parkland

Board Approval Request For Contracts Over $200,000

BOM Date: January 29, 2025	**Product or Service:** Angio-Seal Vessel Products	
Business Owner: Cheston Chan	**Business Owner Dept:** Surgical Administration	**Contract Number:** POCP-24800 A0
Vendor/Supplier/Contractor: Terumo Medical	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Market Price

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	2/1/2025 – 1/31/2028	$975,000
Out Years:	2 Year(s)	+$650,000
Total:	2/1/2025 – 1/31/2030	$1,625,000

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source
If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes
Does this contract have an IT Component? No
Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, and vendor does not have a corporate plan.
Were M/WBE's Directly Solicited? N/A-no solicitation performed
Number Responding M/WBE's: N/A-no solicitation performed
What % of this contract is M/WBE? 0%
M/WBE Race/Ethnicity? N/A
M/WBE Gender? N/A

Submitted By (Division VP): David Alexander, Senior Vice President, Nursing, Executive Nursing Leadership

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Angio-Seal Vessel Products

VENDOR: Terumo Medical

COST:		
	Base Term:	$975,000
	Out Years:	+ $650,000
	Total:	$1,625,000

Recommendation
Approve this contract for Angio-Seal Vessel Products.

Background
This contract is to purchase Terumo items used by the Operating Room, Interventional Radiology, and Cath Lab. The vessel closure devices quickly seal the femoral artery punctures following catheterization procedures allowing for early ambulation (walking).

Fair and Reasonable Price Determination
Although the item being purchased is a sole source for the reasons discussed below, this item is sold in substantial quantities in the commercial marketplace. Market research conducted through ECRI shows that the Parkland price is average as compared to other member hospitals. ECRI is a reputable, private benchmarking firm that collects pricing data covering numerous medical services and products.

Financial Forecast

Base Term	**FY2025**	**FY2026**	**FY2027**	**FY2028**	**FY2029**	**FY2030**	**Totals**
Expenses / Consumables	$216,667	$325,000	$325,000	$108,333			$975,000
Out Years	**FY2024**	**FY2025**	**FY2026**	**FY2027**	**FY2028**	**FY2029**	**Totals**
Expenses / Consumables				$216,667	$325,000	$108,333	$650,000
Grand Totals	**$216,667**	**$325,000**	**$325,000**	**$325,000**	**$325,000**	**$108,333**	**$1,625,000**

Sole Source Justification
This contract is for a good for which there is only one acceptable source. Angio-Seal has no competition.

Document Contact/Author:	Bryson Hendrix

Board Approval Request For Modification to Contract or Funding

BOM Date: January 29, 2025	**Modification:** Mod # 1 Extend Contract for two (2) years and add funding.	
Business Owner: Cheston Chan	**Business Owner Dept:** Peri-op Services	**Contract Number:** POCP-20393
Vendor/Supplier: Texas Practitioners LLC **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	BOM Approved Contract Total (2/22/2023):	$725,319
Revenue, Expense or Capital: Expense	Modification # 1 Amount:	$375,000
Original Start Date: 2/22/2023 **Current Expiration:** 2/28/2025 **Mod Start Date:** 3/1/2025 **Expiration after this Mod:** 2/28/2027	New Contract Amount:	$1,100,319

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): David Alexander, Senior Vice President, Nursing, Executive Nursing Leadership

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # 1 Extend Contract for two (2) years and add funding.

VENDOR: Texas Practitioners LLC

COST:

BOM Approved Contract Total (2/22/2023):	$725,319
Modification # 1:	+ $375,000
Total:	$1,100,319

Recommendation
Approve this contract modification to Extend Contract for two (2) years and add funding..

Background
This contract is for Surgical First Assistant Services. This is an organization which provides personnel to assist in the Operating Room (OR). The personnel are trained as “surgical first assistants” whom are surgical RNs and/or surgical scrub technicians and will manly assist surgeons in robotics and urology but can be utilized in other surgical service lines.

Fair and Reasonable Price Determination
This service is being purchased as a sole source for the reasons below and the pricing is in line with the services offered for these specialty skills. The Surgical First Assistants can be used “as needed” specifically for the duration of the cases required.

Traditionally residents were relied on to do the majority of this work however with the current constraints of needing to provide protected educational time, there are more open slots where a First Assist is needed. This option is more fiscally prudent as they are paid only for work done and there is no additional incurred cost such as benefits.

Financial Forecast

Current Contract Amount	FY2025	FY2026	FY2027	Total
$725,319	$109,375	$187,500	$78,125	$1,100,319

Sole Source Justification
This contract is for a good or service for which there is only one acceptable source as the Surgical First Assistants are specifically trained and credentialed in various surgical specialties.

Document Contact/Author:	Andrea Henley

Board Approval Request For Modification to Contract or Funding

BOM Date: January 29, 2025	**Modification:** Mod # 1 Apheresis kits and sterile solution	
Business Owner: Tanisha Tatum	**Business Owner Dept:** Apheresis Department	**Contract Number:** POCP-24716 A1
Vendor/Supplier: Therakos **Basis of Original Contract Award** Sole Source **Basis of this Modification** Sole Source Modification	Current Contract Amount:	$184,331
Revenue, Expense or Capital: Expense	Modification # 1 Amount:	$386,627
Original Start Date: 9/28/2024 **Current Expiration:** 2/28/2025 **Mod Start Date:** 3/1/2025 **Expiration after this Mod:** 1/31/2026	New Contract Amount:	$570,958

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Judy Herrington, Senior Vice President, Nursing

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Mod # 1 Apheresis kits and sterile solution

VENDOR: Therakos

COST:		
	Current Contract Amount:	$184,331
	Modification # 1:	+ $386,627
	Total:	$570,958

Recommendation
Approve this contract modification to Apheresis kits and sterile solution.

Background
This contract is for apheresis supplies, apheresis kits and apheresis sterile solution. The THERAKOS CELLEX Photopheresis System is a specialized medical procedure primarily used to treat patients with cutaneous T-cell lymphoma (CTCL) who have not responded to other treatments. Apheresis kits are used to separate blood into its' components for the purpose of removing or replacing certain parts of the blood. This is used by our Pharmacy and Apheresis Departments.

Fair and Reasonable Price Determination
Prices were benchmarked above average; however, discounts are based on 12-month usage. Per the vendor, our 12-month usage is not enough to warrant a discount.

Financial Forecast

Current Contract Amount	FY2025	FY2026	FY2027
$184,331	$245,895	$140,732	$570,958

Sole Source Justification
This contract is for a good or service for which there is only one acceptable source. The products/services are additions or modifications to existing systems or equipment where there are no substitute or interchangeable components, software, or maintenance sources and compatibility is paramount. We currently use Uvadex and the kits and will continue to do so.

Document Contact/Author:	Stephanie Toth

Board Approval Request For Contracts Over $200,000

BOM Date: January 29, 2025	**Product or Service:** Construction Manager at Risk (CMAR) for Lab Consolidation	
Business Owner: Marc Leediker	**Business Owner Dept:** Planning, Design and Construction	**Contract Number:** POCRE-24601
Vendor/Supplier/Contractor: Swinerton Builders	**Source Selection Methodology:** Request for Qualifications	**Fair and Reasonable Price Determination:** Adequate Competition

Revenue, Expense or Capital:

Capital

	Contract Dates	Contract Price
Base Term:	2/1/2025 – 3/31/2026	$10,106,000
Out Years:	0 Year(s)	+$0
Total:	2/1/2025 – 3/31/2026	$10,106,000

Lowest Bidder

Is this contractor the lowest bidder/supplier?	N/A-Request for Qualifications
If not, what premium will be paid for this contract over the lowest bidder?	N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency?	Yes
Does this contract have an IT Component?	Yes; and IT approved
Does this contract have a Construction Component?	Yes; and Construction is approved

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Potential for M/WBE engagement:	Vendor will have M/WBE participation. The plan/program has been submitted and accepted.
Were M/WBE's Directly Solicited?	Yes
Number Responding M/WBE's:	0
What % of this contract is M/WBE?	30%
M/WBE Race/Ethnicity?	TBD
M/WBE Gender?	TBD

Submitted By (Division VP): Lance Mendiola, Interim Vice President of Construction, Facilities Management and Real Estate

DALLAS COUNTY HOSPITAL DISTRICT PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Construction Manager at Risk (CMAR) for Lab Consolidation

VENDOR: Swinerton Builders

COST:		
	Base Term:	$10,106,000
	Out Years:	+ $0
	Total:	$10,106,000

Recommendation
Approve this contract for Construction Manager at Risk (CMAR) for Lab Consolidation.

Background
This contract is for the hiring of a Construction Manager at Risk (CMAR) for the Lab Consolidation project. A CMAR will perform preconstruction services and administer the construction work on behalf of the District and is required to competitively award all of the construction work through subcontracts.

This project will expand the current Main Lab on the 2nd floor of the Logistics Building and allow for volumes currently handled by the Rapid Response Lab (RRL) to be migrated to the new expanded Main Lab. As part of the consolidation the SwissLog pneumatic tube system will be upgraded with additional capacity and speed. The Lab Consolidation projected total project estimate is $10,106,000 but pre-construction services are needed to confirm the cost. The CMAR will competitively award all of the construction work through bid packages creating a Guaranteed Maximum Price (GMP) for the project, Pre-Construction services and Construction Fee are included in the total.

Fair and Reasonable Price Determination
A fair and reasonable price was determined through adequate competition. The costs have been reviewed by the Facilities team and a Fair and Reasonable price was determined through historical pricing for similar construction projects and the District's internal estimates. Based on Parkland's internal knowledge and assessment of the costs, the costs are in line with the market.

Vendor	Key Strengths	Key Weaknesses	Non-Cost Score Max 500 pts.
Swinerton Builders	More relevant laboratory experience, project methodology. Impressive safety record		458
Vendor B	Prior Parkland experience	No pre-construction timeline. Incomplete team	388

Financial Forecast

Base Term	FY2025	FY2026	Totals
Expenses	$7,349,818	$2,756,182	$10,106,000

Document Contact/Author:	Steve Adrian

Board Approval Request For Contracts Over $200,000

BOM Date: January 29, 2025	**Product or Service:** Declaration of Access and Drainage Agreement (Easement Agreement)	
Business Owner: Beall Carothers	**Business Owner Dept:** Planning Design & Construction	**Contract Number:** POCRE-25057
Vendor/Supplier/Contractor: Parkland Health	**Source Selection Methodology:** Real Estate – Exemption	**Fair and Reasonable Price Determination:** Market Price

Revenue, Expense or Capital:

Expense: Court Approval

	Contract Dates	Contract Price
Base Term:	1/1/2025 – no expiration date	$0
Out Years:	0 Year(s)	+$0
Total:	1/1/2025 – no expiration date	$0

Lowest Bidder

Is this contractor the lowest bidder/supplier? No
If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes
Does this contract have an IT Component? No
Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? N/A-Zero Dollar
FTE Impact: None

Diversity

Potential for M/WBE engagement: N/A-Real Estate
Were M/WBE's Directly Solicited? N/A-no solicitation performed
Number Responding M/WBE's: N/A-no solicitation performed
What % of this contract is M/WBE? 0%
M/WBE Race/Ethnicity? N/A
M/WBE Gender? N/A

Submitted By (Division VP): Lance Mendiola, Interim Vice President of Construction, Facilities, Real Estate, Operations Administration

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Declaration of Access and Drainage Agreement (Easement Agreement)

VENDOR: Parkland Health

COST:		
	Base Term:	$0
	Out Years:	+ $0
	Total:	$0

Recommendation
Approve this contract for Declaration of Access and Drainage Agreement (Easement Agreement).

Background
Related to the OK Paper Parking Lot project, The City of Dallas is requiring Parkland to enter into a mutual access and drainage easement between the two parcels the project encompasses located at 2420 and 2424 Butler Street. The mutual access and drainage agreement is to manage storm water flow among the parcels to mitigate the potential for flooding due to the site's adjacency to DART right of way which includes Cedar Branch runoff corridor.

Fair and Reasonable Price Determination
N/A – real estate exemption

Financial Forecast

Base Term	FY2025 and beyond	Totals
Expenses / Consumables	$0	$0
Grand Totals	**$ 0**	**$0**

Sole Source Justification
N/A – real estate exemption

Contract Award without Competition Justification
N/A – real estate exemption

Exempt from Competition Justification
N/A – real estate exemption

Contract Extension without Competition Justification
N/A – real estate exemption

Document Contact/Author:	Beall Carothers, Director Real Estate Development

Parkland

Board Approval Request For Contracts Over $200,000

BOM Date: January 29, 2025	**Product or Service:** Vendor Support Services for VMware by Broadcom Virtual Server Infrastructure (Deployment, Adoption, and Support Services)	
Business Owner: Jeff Maxfield / Jeff DeFord	**Business Owner Dept:** Information Technology	**Contract Number:** POIT-24986
Vendor/Supplier/Contractor: CA, Inc. a Broadcom Company	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Historical Pricing

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	Last signature – Three years	$1,000,000
Out Years:	0 Year(s)	+$0
Total:	Last signature – Three Years	$1,000,000

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source
If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes
Does this contract have an IT Component? Yes, and IT approved
Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes
FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, and vendor does not have a corporate plan.
Were M/WBE's Directly Solicited? N/A-no solicitation performed
Number Responding M/WBE's: 0
What % of this contract is M/WBE? 0%
M/WBE Race/Ethnicity? N/A
M/WBE Gender? N/A

Submitted By (Division VP): Joe Longo, Senior Vice President & Chief Information Officer

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: Vendor Support Services for VMware by Broadcom Virtual Server Infrastructure (Deployment, Adoption, and Support Services)

VENDOR: CA, Inc. a Broadcom Company

COST:

Base Term:	$1,000,000
Out Years:	+ $0
Total:	$1,000,000

Recommendation
Approve this contract for Vendor Support Services for VMware by Broadcom Virtual Server Infrastructure (Deployment, Adoption, and Support Services).

Background
Broadcom's VMware technology, which provides server virtualization and cloud infrastructure, is the core technology behind all the servers at Parkland. Support services must be obtained directly from the vendor due to Broadcom's acquisition of VMware. Previously, these services were bundled with licensing and procured through Carahsoft, offering technical support, deployment, adoption, and other support services. Without these services, we wouldn't be able to seek vendor assistance for technical issues for 96% of Parkland's server infrastructure.

Fair and Reasonable Price Determination
Upon reviewing the previous five-year contract, we observed an expected 3.49% annual increase which is considered reasonable as it aligns with inflation rates and industry-specific trends. It is important to note that there are no competitors in this space offering the full range of software and solutions that VMware provides. Market research conducted through ECRI reflects no expressed interest in a comparable services agreement. ECRI is a reputable, private benchmarking firm that collects data covering numerous medical services and products.

Financial Forecast

Base Term	FY2025	Totals
Support Services	$1,000,000	$1,000,000

Sole Source Justification
Importance of VMware Deployment, Adoption, and Support Services:

VMware products are essential for maintaining the stability, security, and performance of our virtualized server infrastructure. Our technical support team will require assistance from the vendor in resolving issues. This ongoing need for vendor support is crucial to effectively manage and integrate the latest advancements in their software.

The contract provides critical support services provided by VMware by Broadcom including technical assistance, software updates, security patches, and access to subject matter expertise. These support services are crucial for ensuring that our systems operate efficiently and without interruption, which is vital for our organization's operations.

Exclusive Source: VMware support can only be purchased from VMware by Broadcom due to the following reasons:

1. **Vendor Exclusivity:** VMware is the sole authorized provider of its products and support services.
2. **Specialized Expertise:** The vendor possesses unique expertise and resources that are specifically tailored to its products. This includes access to proprietary tools, knowledge bases, and technical staff who are trained and certified by VMware.
3. **Integrated Services:** VMware offers integrated support services that are designed to work seamlessly with our existing infrastructure. This integration ensures compatibility and optimizes the performance of our systems.
4. **Continuity of Service:** Transitioning to a different provider would result in significant disruptions and potential downtime. VMware's established support framework provides continuity and minimizes the risk of service interruptions.

Document Contact/Author:	Farrah Smith

Board Approval Request For Contracts Over $200,000

BOM Date: January 29, 2025	**Product or Service:** VMWare Workspace ONE Horizon Licensing	
Business Owner: Jeff Maxfield / Jeff Deford	**Business Owner Dept:** Information Technology	**Contract Number:** POIT-24985
Vendor/Supplier/Contractor: Carahsoft Technology Corp.	**Source Selection Methodology:** Sole Source	**Fair and Reasonable Price Determination:** Historical Pricing, State of TX DIR

Revenue, Expense or Capital:

Expense

	Contract Dates	Contract Price
Base Term:	12/27/2024 – 12/26/2027	$2,852,619
Out Years:	0 Year(s)	+$0
Total:	12/27/2024 – 12/26/2027	$2,852,619

Lowest Bidder

Is this contractor the lowest bidder/supplier? N/A-Sole Source
If not, what premium will be paid for this contract over the lowest bidder? N/A

Approvals

Has the final contract been approved by Legal for legal sufficiency? Yes
Does this contract have an IT Component? Yes; and IT approved
Does this contract have a Construction Component? No

Financial

Is Funding included in the applicable FY Budget? Yes
FTE Impact: None

Diversity

Potential for M/WBE engagement: Vendor self performs; there are no opportunities through subcontractors, but supplier diversity received their corporate plan.
Were M/WBE's Directly Solicited? N/A-no solicitation performed
Number Responding M/WBE's: 0
What % of this contract is M/WBE? 0%
M/WBE Race/Ethnicity? N/A
M/WBE Gender? N/A

Submitted By (Division VP): Joe Longo, Senior Vice President & Chief Information Officer

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

Parkland

SUBJECT: VMWare Workspace ONE Horizon Licensing

VENDOR: Carahsoft Technology Corp.

COST:		
	Base Term:	$2,852,619
	Out Years:	+ $0
	Total:	$2,852,619

Recommendation
Approve procurement of VMWare Workspace ONE Horizon Licensing .

Background
VMware's Workspace ONE Horizon technology is a virtualization and cloud computing software stack that allows multiple virtual machines (VMs) to run on a single physical server and is replete with management and availability tools that are essential for a critical healthcare environment.

This technology provides Parkland's shared clinical desktops, enabling us to efficiently manage resources and improve operational reliability. The software licenses and capabilities are essential to hospital operations and have been in use at Parkland since we opened new Parkland Hospital. These virtual workstations are commonly known as "tap and go" clinical workstations are at every clinical point of care.

Fair and Reasonable Price Determination
Upon reviewing the previous five-year contract, we observed an expected 3.49% annual increase which is considered reasonable as it aligns with inflation rates and industry-specific trends. It is important to note that there are no competitors in this space offering the full range of software and solutions that VMware provides. Market research conducted through ECRI shows that Parkland price is consistent with previous Workspace ONE offers. ECRI is a reputable, private benchmarking firm that collects data covering numerous medical services and products. A fair and reasonable price was determined through adequate competition.

Financial Forecast

Base Term	FY2025	Totals
Software as a Service	$2,852,619	$2,852,619

Sole Source Justification
Importance of VMware Products: The existing VMware products are essential for maintaining the stability, security, and performance of our virtualized desktop infrastructure. The products and corresponding support services provided by VMware include usage entitlements for the suite of products, technical assistance, software updates, security patches, and access to deep subject matter expertise. These services are crucial for ensuring that our systems operate efficiently and without interruption, which is vital for our organization's operations.
Exclusive Source: The capabilities in this suite of products are unique and are currently utilized and relied upon by this organization for 10-plus years. Changing to new or less complete solution from other providers would introduce significant risks and disruption to the organization.

Conclusion: Given the critical importance of VMware Workspace ONE Horizon products and support for our operations and the exclusive nature of VMware's services, it is in the best interest of our organization to procure these products. This sole source procurement will ensure that we receive the highest quality products and support, maintaining the stability and security of our virtualized infrastructure.

Document Contact/Author:	Farrah Smith

Board Approval Request For Modification to Contract or Funding

BOM Date: January 29, 2025	**Modification:** Mod # 1 Claim Scrubber and Eligibility RTE	
Business Owner: Gerry Baker	**Business Owner Dept:** Patient Financial Services	**Contract Number:** PONCS-23854 A3
Vendor/Supplier: Waystar, Inc. **Basis of Original Contract Award** Request for Proposals (Best Value) **Basis of this Modification** Non-Sole Source Modification	BOM Approved Contract Total (6/20/2024):	$2,677,877
Revenue, Expense or Capital: Expense	Modification # 1 Amount:	$3,571,452
Original Start Date: 6/27/2024 **Current Expiration:** 6/26/2027 **Mod Start Date:** Last Signature **Expiration after this Mod:** 6/26/2027	New Contract Amount:	$6,249,329

Approvals

Has the final modification been approved by Legal for legal sufficiency?	Yes
Does this modification have an IT Component?	No
Does this modification have a Construction Component?	No

Financial

Is Funding included in the applicable FY Budget?	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
FTE Impact:	None

Diversity

Current M/WBE Participation?	0%
M/WBE Race/Ethnicity?	N/A
M/WBE Gender?	N/A

Submitted By (Division VP): Gerry Baker, Senior Vice President, Revenue Cycle

Parkland

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH BOARD BRIEFING DOCUMENT

SUBJECT: Mod # 1 Claim Scrubber and Eligibility RTE

VENDOR: Waystar, Inc.

COST:

BOM Approved Contract Total (6/20/2024):	$2,677,877
Modification # 1:	+ $3,571,452
Total:	$6,249,329

Recommendation
Approve this contract modification to Claim Scrubber and Eligibility RTE.

Background
These services were originally offered when negotiations began with Waystar however the Business Owner elected to not include the services at that time due to the urgency of replacing the incumbent (Change Healthcare) who recently had a security breach. The additional services are being implemented in a phased approach.

Parkland is purchasing the following additional services: (i) Analytics (Propensity to Pay); (ii) Coverage Detection; (iii) Prior Authorization; and (iv) Charity Screening. These additional services will be added to our existing contract for Claim Scrubber and Eligibility RTE. The services will assist in increasing the amount and accuracy of patient collections at the time of service.

Fair and Reasonable Price Determination
The cost for these services will be honored at a lower rate until 1/312025. It is in Parkland's best interest to lock in these prices prior to the deadline.

Financial Forecast

Current Contract Amount	FY2025	FY2026	FY2027	FY2028	FY2029	Total
$2,677,877	$714,290	$714,290	$714,290	$714,290	$714,292	$6,249,329

Document Contact/Author:	Baruh Bosch

CONTRACT RESOLUTION
Board of Managers
January 29, 2025

PARKLAND HEALTH

RESOLUTION NO. _____

Be it resolved, the Parkland Health Board of Managers, by a vote of _____ Yes and _____ Nay, does by this resolution (adopt/reject) _____ the following:

WHEREAS, Parkland Health management requested approval for certain contracts and approval/rejection is as checked below:

Approved	Rejected	Withdrawn	Type	Service or Product	Vendor	Contract Term	Aggregate Contract Amount Approved	Budgeted
			Expense	Mod to Add Funds #3 Venaseal & ClosureFast Products	Medtronic USA, Inc.	10/30/2024 - 12/23/2025	$249,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod to Add Funds 1 WALRUS balloon catheters	Q'Apel Medical, Inc.	3/2/2023 - 3/1/2026	$87,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod # 5 Intravascular Lithotripsy ("IVL") Products	Shockwave Medical Inc.	10/25/2023 - 3/1/2027	$1,200,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod # 7 Radial align, stems, and screws for orthopedic implants	Skeletal Dynamics	7/26/2023 - 1/31/2027	$1,400,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Capital	Lifepack CR2 semi-automatic Automated External Defibrillators	Stryker Sales, LLC	Last Signature – 12/31/2025	$243,228	Yes
			Expense	Mod # 3 Blood apheresis disposables/consumables	Terumo BCT	10/25/2023 - 12/31/2025	$353,289	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Angio-Seal Vessel Products	Terumo Medical	2/1/2025 – 1/31/2028	$1,625,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod # 1 Extend Contract for two (2) years and add funding	Texas Practitioners LLC	2/22/2023 - 2/28/2027	$375,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense	Mod # 1 Apheresis kits and sterile solution	Therakos	9/28/2024 - 1/31/2026	$386,627	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Capital	Construction Manager at Risk (CMAR) Pre-construction fees for Lab Consolidation	Swinerton Builders	2/1/2025 – 3/31/2026	$10,106,000	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.
			Expense: Court Approval	Declaration of Access and Drainage Agreement (Easement Agreement)	Parkland Health	1/1/2025 – no expiration date	$0	N/A-Zero Dollar
			Expense	VMware Customer Portfolio Manager (Support Services)	CA, Inc. a Broadcom Company	Last signature – Three years	$1,000,000	Yes
			Expense	VMware Workspace One Mobile Essentials SaaS	Carahsoft Technology Corp.	12/27/2024 – 12/26/2027	$2,852,619	Yes
			Expense	Mod # 1 Claim Scrubber and Eligibility RTE	Waystar, Inc.	6/27/2024 - 6/26/2027	$3,571,452	Yes, for the current fiscal year. Additional years costs will be budgeted in the appropriate fiscal year budgets.

THEREFORE, BE IT RESOLVED, that the Parkland Health Board of Managers approves these contracts as noted.

Dated this 29th of January 2025.

Marjorie D. Petty, JD
Chair

Steve Roth, JD, MPH
Assistant Secretary

Marjorie Petty, JD	Yes _____	No _____	Abstain _____	Absent _____
Elizabeth Palacios, MD	Yes _____	No _____	Abstain _____	Absent _____
Todd Furniss, JD	Yes _____	No _____	Abstain _____	Absent _____
Eric G. Bing, MD, PhD	Yes _____	No _____	Abstain _____	Absent _____
Byron Cryer, MD	Yes _____	No _____	Abstain _____	Absent _____
Reina Gonzalez, JD	Yes _____	No _____	Abstain _____	Absent _____
Vincent Hall	Yes _____	No _____	Abstain _____	Absent _____
Ramon Miguez, PE	Yes _____	No _____	Abstain _____	Absent _____
Farida Minner, RN	Yes _____	No _____	Abstain _____	Absent _____
John Proctor	Yes _____	No _____	Abstain _____	Absent _____
Lisa Sutter	Yes _____	No _____	Abstain _____	Absent _____

Consideration and Appropriate Action Regarding Capital Substitutions

Parkland Health
FY2025 Capital Substitution
For January 2025 Board Meeting

Ref #	Division	Project Total	Substitution Amount	Description
1	ED & Behavioral Health	$1,056,292	$206,292	**Construction of An Expanded Psych Intake Area**
	Explanation	This is a previously approved project to expand the psych intake area. The goal of the project is to ensure a safe environment for patients and staff. The request includes the following additions: de-escalation hallway (1), triage/medical screening room (1), expanded waiting area and exam rooms (2). Several issues were revealed during ceiling demolition, which include a height discrepancy, structural steel conflict with the proposed design, and a mismatch with the HVAC ductwork. These issues result in additional work to be performed, which include the following: removal of the existing ceiling, fire suppression system; rebuilding the ductwork (substantial increase), electrical systems, and plaster ceilings; structural steel modification; wall assembly modifications.		
	Driver(s) of Increased Expense:	Issues identified during ceiling demolition which require correction: height discrepancy on the exterior block wall; structural steel conflict with the proposed design; mismatch with HVAC ductwork.		
	Description of Item:	Renovation of the psych intake area		
2	Information Technology	$696,268	$696,268	**Notebook Thinkpads (400)**
	Explanation	The IT Fulfillment team purchased a bulk order of laptops (400) in order to get discounted pricing. The original price per unit was $2,980.60. The discounted unit price is $1,740.67. This yields savings of $1,239.93 per unit or a total savings of $496K. These items were budgeted as minor equipment as previous laptop purchases had not been considered capital. The bulk purchase of the laptops (400) qualifies as a capital purchase under the current capital asset guide. The laptops have a useful life of three years, and the annual depreciation expense will be $232,089.		
	Driver(s) of Increased Expense:	Change in the bulk capital policy		
	Description of Item:	Laptop computers (400)		
	Grand Total	**$1,752,560**	**$902,560**	

PARKLAND HEALTH

RESOLUTION NO. _____

Be it resolved, the Parkland Health Board of Managers, by a vote of _____ Yes and _____ Nay, does by this resolution (adopt/reject) _____ the following:

WHEREAS, Parkland Health management requests approval for the use of contingency funds for capital items in the amount of $1,752,560 for FY25 as itemized in the listing presented to the Board of Managers, and

THEREFORE, BE IT RESOLVED, that the Parkland Health Board of Managers approves the use of funds as submitted.

Dated this ____th Day of _____2025.

_____
Marjorie Petty, JD
Chair

_____
Steven Roth, JD, MPH
Assistant Secretary

Marjorie Petty, JD	Yes_____	No _____	Abstain _____	Absent _____
Elizabeth Palacios, MD	Yes_____	No _____	Abstain _____	Absent _____
Todd Furniss, JD	Yes_____	No _____	Abstain _____	Absent _____
Eric G. Bing, MD, PhD	Yes_____	No _____	Abstain _____	Absent _____
Byron Cryer, MD	Yes_____	No _____	Abstain _____	Absent _____
Reina Gonzalez, JD	Yes_____	No _____	Abstain _____	Absent _____
Vincent Hall	Yes_____	No _____	Abstain _____	Absent _____
Ramon Miguez, PE	Yes_____	No _____	Abstain _____	Absent _____
Farida Minner, RN	Yes_____	No _____	Abstain _____	Absent _____
John Proctor	Yes_____	No _____	Abstain _____	Absent _____

Consideration and Appropriate Action Regarding Fiscal 8311-1-15 Supplemental Retirement Plan Investment Policy

Fiscal 8311-1-15 Supplemental Retirement Plan Investment Policy

Requirements regarding this document are found in:

- The Texas Health & Safety Code 281.049

Background:

- Last published 1/26/24 (3-year approval period), but we have a new consultant firm, which necessitates changes now..

Revisions:

The Investment Committee reviewed and recommended modifications ahead of the next triennial review.

- Change document name to “Supplemental Savings Plan Investment Policy”
- Removed the Investment Structure illustration
- Updated the name of the Investment Consultant
- Replaced the former consultants’ illustration with the new consultants’ illustration

Approvals:

- Joe Mayer, Treasury Director
- Rick Humphrey, EVP & CFO
- Investment Committee (9/13/24)
- Board Budget and Finance Committee (scheduled 12/17/24)
- Board of Managers (scheduled 1/29/25)

Supplemental ~~Retirement~~ Savings Plan Investment Policy	8311-1-15	Published: 01/26/24
Fiscal		Page **1** of **11**

Background and Purpose

The Dallas County Hospital District, dba: Parkland Health ("Parkland") sponsors 457(b), 403(b) and 401(a) plans known as the Parkland Supplemental Savings Plan for employees who are eligible to participate. This document also includes Parkland's Mandatory Savings Plan organized as a 401(a) Social Security replacement plan for all new full-time employees hired after December 12, 2023 and part-time employees working after this date. These four plans are collectively referred to as "Plans" in this document and are subject to the same investment standards and group of investment funds.

The purpose of this Investment Policy Statement ("IPS") is to assist Parkland's Board of Managers ("Board") in effectively establishing, monitoring, evaluating, and revising the investment program established for the Plans. The Board has the authority to oversee the investment of the Plans' assets and will discharge its responsibilities under the Plans solely in the interests of the Plans' participants and their beneficiaries.

This IPS may be modified from time to time by action of the Board. The policy identifies a set of investment objectives, guidelines, and performance standards for the investment of the Plans' assets. The purpose is to facilitate decision making with respect to investments.

This IPS does not create or imply any contract between Parkland and/or the Board and any participant. If there is any conflict between this IPS and the Plan Document, the terms and conditions of the Plan Document will control.

Roles and Responsibilities

Board of Managers

The responsibility for the Plans rests with the Board. The Board is broadly responsible for overseeing the administration of the Plan and its investment options. Its duties include establishing an investment policy, hiring service providers, and evaluating the success of service providers in carrying out the policy.

The responsibilities of the Board, as named fiduciary for the Plans, include:

- Establishing the number and types of investment options available to plan participants, including the default investment alternative for participants who fail to make an investment election;
- Identifying investment options within each asset class that it deems appropriate and prudent;
- Monitoring investment results by means of regular reviews and analyses to determine whether the asset classes and investment options offered are meeting the guidelines and criteria identified in this IPS;

DRAFT

Monitoring and evaluating the Plans' expenses;

Ensuring there is a comprehensive employee communication program in place for the participants of the Plans. The communication program provides information to assist participants in making informed decisions regarding the investment of contributions and existing balances among the investment choices offered in the Plans; and

Retaining and monitoring service providers as necessary including, but not limited to, recordkeeper, trustee, investment consultants, and investment managers.

Investment Committee

The Investment Committee ("Committee") shall:

Serve as an investment advisor to the Board;

- Be composed of members who are selected based upon their overall investment experience, including managing or supervising similar-sized investment portfolios, and their willingness to serve as community volunteers without compensation, but with reimbursement for reasonable out-of-pocket expenses incurred in accomplishing their Investment Committee-related duties;
- Be eligible for indemnification related to actions taken within the scope of their duties as members of the Investment Committee, to the fullest extent allowed by applicable law;
- Recommend to the Board appropriate Investment Consultants, Investment Managers, Trustees and Custodians, mutual funds or other vendors to implement the Policy; and
- Suggest investment goals and objectives for the Plans and recommend an appropriate investment structure to be incorporated into this Policy.

Staff

Staff is responsible for the day-to-day management of the Plans; for bringing relevant issues to the attention of the Board; and for working with the appropriate service providers to implement the decisions made by the Board. Specifically, the Staff is responsible for the following:

Managing and monitoring plan activity;

Coordinating the Committee meetings, investment manager presentations and discussions, and investment consultant activities, presentations and discussions with the Committee;

Identifying issues to be brought before the Committee and Board and preparing recommendations on those matters;

DRAFT

Handling other matters periodically as directed by the Committee and Board;

Providing information to the Plans' recordkeeper as appropriate;

Facilitating the audit process by preparing financial statements and acting as an interface between the auditors and various service providers; and

Verifying compliance with guidelines and regulations.

Investment Consultant

The primary role of the investment consultant is to assist the Committee and Staff in fulfilling their responsibilities by providing information, analysis, and recommendations that support a prudent process. The responsibilities of the investment consultants are as follows:

Provide perspectives on capital markets;

Periodically review investment policies and objectives;

Research and recommend structure and investments that are appropriate in furthering the Plans' investment policies and objectives;

Recommend appropriate performance measures and benchmarks and report on the effectiveness of those adopted;

Maintain contact with and report on changes within the investment manager organizations (including the gain or loss of key individuals and accounts);

Measure, evaluate, and report investment managers' performance results;

Monitor recordkeeper and investment option expenses in the context of services provided;

Monitor governance and plan structure and report to the Committee and staff as needed; and

Report quarterly to the Committee.

Recordkeeper

The Recordkeeper provides, among other things:

Suitable and accurate participant recordkeeping and administrative services;

Accurate and timely plan data, information, and reports including required information regarding the Plans' fees;

Notifications regarding concerns or issues with respect to recordkeeping or administrative services;

DRAFT

Information on participant activity;

Required participant notices, tax withholding and deposit, direct rollover, and other requirements relating to the Plans' distributions;

Informational items, such as prospectuses, and;

Enrollment materials, education, and communication, as necessary.

Custodian

The Custodial Trustee will provide (among other things) the following services:

Asset safekeeping;

Pricing;

Reconciliation with investment managers to ensure trades are correct and affirmed;

Settlement of securities transactions;

Collection of income;

Investment accounting services;

Determination of the Net Asset Value for each fund;

Distribution of proxies to appropriate parties;

Communication to Parkland of any concerns or issues with respect to Custodial Trustee Services; and

Periodic holding, transaction, valuation, and performance data at the Plan and Fund levels.

Investment Managers

The specific duties and responsibilities of each of the Plans' investment managers are to manage the assets under their supervision in accordance with the guidelines and objectives outlined in their respective prospectuses, participation agreements or other governing documents (e.g., Investment Management Agreements).

Managers should be responsive to the Board, Committee, Staff, or consultant and provide information as necessary.

Investment Structure Philosophy

DRAFT

Objective

The Plans should offer participants a range of investment options allowing them to construct a diversified portfolio appropriate to the individual's time horizon and risk tolerance.

Menu design facilitates diversified investment by plan participants. As such, menu design will take into account the belief that choices offered affect participants' allocation decisions.

Investment Structure

The Board has chosen to adopt a two-~~tiered~~ pronged investment structure that provides (1) asset allocation options for "do-it-for-me" participants and (2) core asset class building blocks that allow "do-it-yourselfer" participants to create their own asset allocations based on their unique investment profiles.

Asset Allocation Options offer diversification and professional management. The assets of participants who do not make an active selection among the available investment options will be placed in the asset allocation options.

DRAFT

Parkland

Supplemental ~~Retirement~~ Savings Plan Investment Policy	8311-1-15	Published: 01/26/24
Fiscal		Page **6** of **11**

Core Investment Options include the basic building blocks participants need to create a diversified portfolio.





				Small/Mid Cap Equity
				Active Smid Growth & Value Funds
~~Aggressive~~				

DRAFT

Manager Selection Criteria

When selecting investment managers, the Board will employ a prudent search process. This process may include the following steps and/or others that the Board determines appropriate:

Formulation of specific investment manager search criteria that reflect the requirements for the mandate under consideration.

Identification of qualified candidates from the manager search database maintained by the Investment Consultant and other sources.

Analysis of qualified candidates in terms of:

Quantitative characteristics (e.g., return, risk, other relevant portfolio characteristics) and fees relative to similar products or mandates.

Qualitative characteristics such as organization, key personnel, investment philosophy, and decision-making process.

Evaluation of finalist candidates by the Committee based on a thorough due diligence process with an ultimate recommendation to the Board.

Selection and hiring of a finalist by the Board.

Performance Monitoring

On a regular basis, the Committee will review the performance of the Plans' investment options to ensure that they are meeting expectations. In evaluating all investment managers, the Committee will consider qualitative and quantitative factors likely to impact the future performance of the investment option.

If an investment manager fails to meet reasonable standards regarding the following qualitative or quantitative criteria, a formal review may be warranted.

1. **Qualitative issues** to evaluate in an investment manager include:

   Ownership changes (e.g., key people "cash out")

   Departure of key investment professionals

   Changes in the decision-making process

   Changes in investment philosophy

   Involvement in material litigation or fraud

DRAFT

Quantitative Issues to evaluate include underperformance over a full market cycle, changes in risk profile, portfolio characteristics that are inconsistent with expectations and costs that are high relative to stated benchmarks and peers.

The performance of the strategy managed by each Investment Manager is expected to achieve minimum performance standards. Active managers should:

Rank in the top 50% of an appropriate peer group of actively managed portfolios;

Meet or exceed an appropriate benchmark net of management fees;

Maintain a risk level, as measured by the standard deviation of quarterly returns, which is comparable to that of the appropriate benchmark. To the extent that the Investment Manager takes more/less risk than the market and/or the appropriate peer group, returns are expected to increase/decrease commensurately.

These performance measurement standards should be achieved over rolling three- and five-year periods. Although failure to achieve these performance measurement standards will not result in the automatic termination of an Investment Manager, the Committee and the Board shall review any Investment Manager that fails to achieve the standards and shall document its reasons for retaining the Investment Manager and such manager will be placed on a watch list.

A number of factors may contribute to an investment manager's over- or underperformance at any given time, including market dynamics, investment skill, and/or pure chance. It may be imprudent to terminate an investment manager solely for failing to meet performance expectations. Performance could be attributable to factors that do not reflect deficiencies in skills or strategy.

Other Investment Provider Selection

Participant Advice Provider and Managed Account Selection

In selecting an advice or managed account provider, the Board will seek suitable services, organizational stability, a reasonable and transparent investment approach, and appropriate operational capabilities. The provider will also be required to supply necessary support of the advice provided, such as reporting and customer service. On an ongoing basis, the Committee and Board will monitor the provider's process and fees; however, it will not monitor the actual advice provided to individual participants.

Self-directed brokerage account provider selection

Should the Board select a self-directed brokerage account provider, they would evaluate and monitor fees, including annual maintenance charges and trading costs. In addition, the self-directed brokerage provider

DRAFT

would be required to provide appropriate services, such as trading, transactional oversight, and customer service. Because the self-directed brokerage account would not be a designated investment account within the Plans, the Board would not monitor the individual investments or their expenses within the self-directed brokerage account.

The Board will seek to provide participants with access to high-quality investment options with reasonable investment management and administrative expenses relative to services provided.

Investment management expenses will be reviewed periodically to determine whether a lower-cost share class or investment vehicle is available and feasible.

Regarding fees for plan administration:

Participants will pay for the administration of the Plans, and for their own individual plan transactions.

Participants pay fixed dollar administrative fee. Periodically, the Committee will review fee policy and any suggested changes will be recommended to the Board.

The Committee will work with the investment consultant to evaluate investment costs and administrative fees on a periodic basis. This information will be benchmarked appropriately.

Investment Policy Review Procedures

As a general rule, the Committee should review this IPS annually. However, it is not expected that the investment policy will change frequently; in particular, short-term changes in the financial markets generally should not merit an adjustment in the investment policy.

The Appendix will be updated and changed as needed to reflect Board decisions.

DRAFT

Appendix

Plan information and list of current providers as of ~~October 2023.~~September 2024.

Plan Information

Names of Plan(s):	Dallas County Hospital District Supplemental Savings Plan consisting of 457(b), 403(b) and 401(a) plans and the Mandatory Savings Plan organized as a 401(a) Social Security Replacement Plan
Plan Sponsor:	Dallas County Hospital District, dba: Parkland Health
Plan Contact:	Joe Mayer Treasury Director Parkland Health Direct Dial: 214-590-4123 Email: joe.mayer@phhs.org 8435 N. Stemmons Frwy, ~~Suite 900~~ Suite 1140 Dallas, TX 75247
Employer ID Number:	75-600-4221
Recordkeeper:	Milliman U.S.A.
Custodian:	Charles Schwab Bank
Investment Consultant:	~~Callan LLC~~Meketa Investment Group

DRAFT

Consideration and Appropriate Action Regarding 2025 Southwestern Medical District Budget

2024 SOUTHWESTERN MEDICAL DISTRICT RESOLUTION

This Resolution will provide for Parkland's continued participation in the Southwestern Medical District ("SWMD") with Children's and UT Southwestern. Parkland's obligation for the Fiscal Year 2025 budget is $474,232 and covers the following shared expenses that benefit the three participants as outlined in the Operating Agreement:

1. Wayfinding
2. Shared Shuttle Routes
3. Permits, Surveys, Designs, and Easements
4. FDB Drug Database License Agreement
5. Landscaping & Other Maintenance
6. Branding and Marketing

DRAFT

ANNUAL OPERATING CONTRACT

I. CONTRACTING PARTIES:

This contract and agreement, hereinafter referred to as "**Agreement**," is entered into by and between Dallas County Hospital District, located at 5200 Harry Hines Boulevard, Dallas, Texas 75235, hereinafter referred to as "**Parkland**" and Southwestern Medical District, a 501(c)(3) organization incorporated under the provisions of the Texas Non-Profit Corporation Act, located at 5323 Harry Hines Boulevard, Dallas, Texas 75390-9166, hereinafter referred to as "**SWMD**."

II. STATEMENT OF SERVICES TO BE PERFORMED:

The attached **Exhibit 1** sets out the services to be provided by SWMD to Parkland, what initiates the services to be provided, and the payment amount agreed upon for those services.

III. INSURANCE:

SWMD shall maintain comprehensive liability insurance to cover the acts and omissions of its officers, employees and agents during the term of this Agreement, said coverage shall at all times be at least One Million Dollars ($1,000,000) combined single limit per person per occurrence. Parkland shall be self insured at such coverage levels as deemed appropriate. Upon request, each party shall furnish the other with a copy of policies or other evidence of insurance coverage, and shall give at least thirty (30) days' written notice before any such insurance is canceled or changed with respect to such party's coverage or limits of liability.

IV. DISPUTE RESOLUTION:

Parkland and SWMD shall make a good-faith attempt to resolve any claim for breach of contract made by SWMD that cannot be resolved in the ordinary course of business. The Chief Business Officer of Parkland shall examine SWMD's claim and any counterclaim and negotiate with SWMD in an effort to resolve such claims. The parties hereto specifically agree that Parkland has not waived its right to seek redress in the courts.

V. PAYMENT FOR SERVICES:

A. As set out in Exhibit 1, Parkland shall pay SWMD a total of $474,232.00.

B. Payment for services shall be made within thirty (30) days of receipt of an invoice addressed to the Accounts Payable Department, Dallas County Hospital District, 5200 Harry Hines Boulevard, Dallas, Texas, 75235.

VI. MISCELLANEOUS CLAUSES:

A. **Venue; Governing Law.** Dallas County, Texas shall be the proper place of venue for suit on or in respect of the Agreement. The Agreement and all of the rights and

DRAFT

obligations of the parties hereto and all of the terms and conditions hereof shall be construed, interpreted and applied in accordance with and governed by and enforced under the laws of the State of Texas.

B. **Entire Agreement; Modifications.** The Agreement supersedes all prior agreements, written or oral, between SWMD and Parkland and shall constitute the entire Agreement and understanding between the parties with respect to the subject matter hereof. The Agreement and each of its provisions shall be binding upon the parties and may not be waived, modified, amended or altered except by a writing signed by Parkland and SWMD.

VII. TERM OF AGREEMENT:

This Agreement is to begin January 1, 2025 and extend through December 31, 2025 and shall continue thereafter on a year to year basis upon approval of an annual budget, or until terminated by either party with sixty (60) days written notice. This Agreement may be amended from time to time by written agreement of both parties.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the effective date specified herein.

SOUTHWESTERN MEDICAL DISTRICT

By: _____
Daniel K. Podolsky, M.D.
President

Date: _____

DALLAS COUNTY HOSPITAL DISTRICT

By: _____
Richard Humphrey
Executive Vice President and
Chief Financial Officer

Date: _____

DRAFT

EXHIBIT 1

SERVICES TO BE RENDERED BY SOUTHWESTERN MEDICAL DISTRICT

CONSULTING AND OTHER SERVICES

SWMD will provide consulting and other services at the request of Parkland. These services may include access to the First DataBank pharmacy drug database; shared shuttle routes; Manager's salary and benefits; landscaping, maintenance, and tree pruning; branding and marketing; signage maintenance and repair; annual municipal license fees; plans and studies; and other services. In return for these services, Parkland will fund a proportionate amount of the operating costs for SWMD, as well as certain finance & administrative costs including insurance expenses and tax preparation fees.

Parkland shall pay SWMD a total of $474,232.00 for these services.

PARKLAND HEALTH
BOARD OF MANAGERS

RESOLUTION NO. _____

2025 SOUTHWESTERN MEDICAL DISTRICT BUDGET

Be it resolved, the Dallas County Hospital District Board of Managers by a vote of ____ Yes and ___ Nay, does by this resolution (adopt/reject) _____ the following:

WHEREAS, Parkland Health ("Parkland"), UT Southwestern, and Children's Health are members of, and jointly participate in and fund, the Southwestern Medical District ("SWMD"); and

WHEREAS the SWMD supports the common efforts of the three member organizations through wayfinding, shared shuttle routes, common permits, surveys, easements, drug database license, landscaping and other general maintenance, and branding and marketing for the benefit of the medical district, and

WHEREAS the SWMD Board approved the 2025 budget; and

WHEREAS, Management has recommended that the Parkland Board of Managers approve continued participating in the SWMD and authorize the payment of Parkland's share of funding for the SWMD; and

THEREFORE, **BE IT RESOLVED,** that the Parkland Board of Managers approves and authorizes Parkland to fund its share of the 2025 SWMD budget and execution of the 2025 Operating Contract.

Dated this _____ day of _____, _____.

Marjorie Petty, JD Chair	Steven J. Roth Secretary

Marjorie Petty, JD	Yes _____	No _____	Abstain _____	Absent _____
Eric G. Bing, MD, PhD	Yes _____	No _____	Abstain _____	Absent _____
Byron Cryer, MD	Yes _____	No _____	Abstain _____	Absent _____
Todd Furniss, JD	Yes _____	No _____	Abstain _____	Absent _____
Reina Gonzalez, JD	Yes _____	No _____	Abstain _____	Absent _____
Vincent Hall	Yes _____	No _____	Abstain _____	Absent _____
Ramon Miguez, PE	Yes _____	No _____	Abstain _____	Absent _____
Farida Minner, RN	Yes _____	No _____	Abstain _____	Absent _____
Elizabeth Palacios, MD	Yes _____	No _____	Abstain _____	Absent _____
John Proctor	Yes _____	No _____	Abstain _____	Absent _____
Lisa Sutter	Yes _____	No _____	Abstain _____	Absent _____

Consideration and Appropriate Action Regarding Investment Committee Appointments

Resolution No. _____

A RESOLUTION OF THE DALLAS COUNTY HOSPITAL DISTRICT BOARD OF MANAGERS APPROVAL OF INVESTMENT OFFICERS

Be it resolved, the Dallas County Hospital District Board of Managers by a vote of _____ Yea and _____ Nay, Does By This Resolution (adopt/reject) _____ the following:

WHEREAS, the Dallas County Hospital District has established a program for independent investment of its available cash balances and has formulated an Investment Policy to guide this program; and

WHEREAS, the Texas Public Funds Investment Act requires the governing board of each governmental entity to designate by official order those individuals primarily responsible for investing activities of that entity.

NOW, THEREFORE, BE IT RESOLVED by the Board of Managers of the Dallas County Hospital District that the following individuals are hereby authorized to invest District funds as the Dallas County Hospital District's Investment Officers, per the Investment Policy. This authority is extended until rescinded by the District or upon termination of the Investment Officer.

Richard Humphrey	EVP & CFO	_____
Joe Mayer	Treasury Director	_____
Christi Paul	Treasury Manager	_____

Dated this ____th day of _____, 2024.

_____	_____
Marjorie Petty, JD	Steven Roth, JD, MPH
Chairman	Assistant Secretary

Eric G. Bing, MD, PhD	Yes_____	No_____	Abstain_____	Absent_____
Bryon Cryer, MD	Yes_____	No_____	Abstain_____	Absent_____
Todd Furniss, JD	Yes_____	No_____	Abstain_____	Absent_____
Vincent Hall	Yes_____	No_____	Abstain_____	Absent_____
Reina Gonzalez, JD	Yes_____	No_____	Abstain_____	Absent_____
Ramon F. Miguez, PE	Yes_____	No_____	Abstain_____	Absent_____
Farida Minner, RN	Yes_____	No_____	Abstain_____	Absent_____
Elizabeth Palacios, MD	Yes_____	No_____	Abstain_____	Absent_____
Marjorie Petty, JD	Yes_____	No_____	Abstain_____	Absent_____
John Proctor	Yes_____	No_____	Abstain_____	Absent_____
Lisa Sutter	Yes_____	No_____	Abstain_____	Absent_____

Consideration and Appropriate Action Regarding the Delegation of Signature Authority for Certain Matters to Dr. Brett Moran

PARKLAND HEALTH
BOARD OF MANAGERS

RESOLUTION NO. _____

RESOLUTION

Be it resolved, the Dallas County Hospital District Board of Managers by a vote of ____ Yes and ___ Nay, does by this resolution (adopt/reject) _____ the following:

WHEREAS the Dallas County Hospital District is a political subdivision of the State of Texas and does business as Parkland Health ("Parkland"); and

WHEREAS Parkland previously adopted the Purchasing Practices and Procedures Manual ("Manual"), and

WHEREAS Parts 2-201 and 2-203 of the Manual confer authority of the Chief Executive Officer to delegate authority for the efficient administration of contracting functions with the approval of the Parkland Board of Managers; and

THEREFORE, **BE IT RESOLVED,** that the Parkland Board of Managers approves the following delegation of authority:

Brett Moran, M.D., Chief Health Officer, signature authority for: 1) all contracts between Parkland and its affiliate the Parkland Center for Clinical Innovation ("PCCI") that would otherwise fall within the authority of the Chief Executive Officer, including but not limited to subsequent Project Orders governed by said contracts and 2) agreements pertaining to research projects to be conducted at Parkland . This includes without limitation Institutional Signature Official ("ISO") duties required under Parkland's clinical research programs and execution of any required Federalwide Assurance in connection with clinical research at Parkland.

Dated this _____ day of _____, 2025.

Marjorie Petty, JD Chair	Steven J. Roth Assistant Secretary

Marjorie Petty, JD	Yes	_____	No	_____	Abstain	_____	Absent _____
Eric G. Bing, MD, PhD	Yes	_____	No	_____	Abstain	_____	Absent _____
Byron Cryer, MD	Yes	_____	No	_____	Abstain	_____	Absent _____
Todd Furniss, JD	Yes	_____	No	_____	Abstain	_____	Absent _____
Reina Gonzalez, JD	Yes	_____	No	_____	Abstain	_____	Absent _____
Vincent Hall	Yes	_____	No	_____	Abstain	_____	Absent _____
Ramon Miguez, PE	Yes	_____	No	_____	Abstain	_____	Absent _____
Farida Minner, RN	Yes	_____	No	_____	Abstain	_____	Absent _____
Elizabeth Palacios, MD	Yes	_____	No	_____	Abstain	_____	Absent _____
John Proctor	Yes	_____	No	_____	Abstain	_____	Absent _____
Lisa Sutter	Yes	_____	No	_____	Abstain	_____	Absent _____

Consideration and Appropriate Action Regarding the Revised 2025 Audit Plan

Revised FY 2025 Audit Plan

2024 Carry Forward

- Assets
- Contract Labor – New Process
- Cigna – Claims Review

Annual

- Cash Monitoring (Fraud)
- HIPAA Privacy (Collaboration with Compliance)
- Physical Inventory
- External Audit (Interim & Final)
- Follow-up Monitoring
- Annual Audit Plan
- Enterprise Risk Management (ERM)
- IAS Quality Assurance Review
- Software Implementation - Finalize

Affiliate

- ~~PCCI (Risk)~~
- PCHP – Claims Payment
- ~~Foundation – Parkland Focus Funds~~
- PCHP – OIG Corrective Action Plan
- PCHP – AUP Financial Reporting CAP
- PCHP – HIPAA Privacy and Security Collaboration
- PCHP – Provider Data Management

Projects

- Patient Registration
- Construction Project Review
- Revenue Cycle – Professional Billing
- Third-Party Contract Management
  (expanded to include PCHP-specific topics)
- Charge Master – Procedural Areas
- ~~Workforce Management~~
- Information Security (Cyber, Risk, Collaboration with IT)
- Cause Analysis Validation (TBD – collaboration with Quality)
- ~~Supply Chain (Risk)~~
- UT Contract (Risk, MSA Documentation Review)

Consideration and Appropriate Action Regarding Medical Executive Committee Resolution for Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers

DALLAS COUNTY HOSPITAL DISTRICT
PARKLAND HEALTH

RESOLUTION NO. _____

RESOLUTION

Be it resolved, the Dallas County Hospital District Board of Managers by a vote of _____YES and ____ NAY, does by this resolution (adopt/reject) _____the following:

WHEREAS, the Medical Executive Committee recommends approval of the Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers as presented.

THEREFORE BE IT RESOLVED that the Board of Managers approves the recommended Appointments/Reappointments, Privileges and Staff Status Changes of the Medical Staff and Non-Physician Clinical Providers.

Dated this 29th of January 2025

_____	_____
Marjorie D. Petty, JD	Steve Roth, JD, MPH
Chair	Assistant Secretary

Marjorie D. Petty, JD	Yes_____ No_____ Abstain _____Absent_____
Elizabeth Palacios, MD	Yes_____ No_____ Abstain _____Absent_____
Todd Furniss, JD	Yes_____ No_____ Abstain _____Absent_____
Eric G. Bing, MD, PhD	Yes_____ No_____ Abstain _____Absent_____
Byron Cryer, MD	Yes_____ No_____ Abstain _____Absent_____
Reina Gonzalez, JD	Yes_____ No_____ Abstain _____Absent_____
Vincent Hall	Yes_____ No_____ Abstain _____Absent_____
Ramon Miguez, PE	Yes_____ No_____ Abstain _____Absent_____
Farida Minner, RN	Yes_____ No_____ Abstain _____Absent_____
John Proctor	Yes_____ No_____ Abstain _____Absent_____
Lisa Sutter	Yes_____ No_____ Abstain _____Absent_____

Strategic Facilities Plan Vision Statement and Tradeoffs Exercise

Parkland Health

Strategic Facilities Plan

Board of Managers

January 29, 2025

BLUE COTTAGE
of CannonDesign

© 2025 The Cannon Corporation | All rights reserved

Today’s Agenda

1. Progress To Date
2. Review of Aspirations, Project Vision & Focus Areas
3. Trade-off Activity
4. Next Steps

© 2025 The Cannon Corporation | All rights reserved

Project Schedule



Current State Assessment

- ✓ Project Initiation
- ✓ Metrics of Success
- ✓ Develop Data Request
- ✓ Interviews/Observations
- ✓ Strategic Visioning
- ✓ Facility and Site Assessment
- ✓ Current Space Needs
- ✓ Capacity & Utilization
- \+ **Gap Analysis**

Future State

- ✓ Service Area Assessment and Demographics
- ✓ Utilization Trend Analysis
- ✓ Market Growth Projections
- \+ **Service Line Distribution**
- \+ **New Services and Revenue Generating Opportunities**
- \+ **Future Key Rooms**
- \+ **Future Space Needs**
- \+ **Adjacencies & Proximities**

Option Development/ Assessment

- \+ Scenario Development
- \+ Highest & Best Use
- \+ Facility Re-use and Life Cycle Analysis
- \+ On-Campus vs Off-Campus
- \+ Site Options
- \+ Capital Needs and Cost Estimates
- \+ Timeline/Phasing
- \+ Advantages & Disadvantages

Final Recommendation and Approval

- \+ Preferred Scenarios
- \+ Recommendations and Board Approval
- \+ Documentation

✓ Complete
\+ **In Progress**

© 2025 The Cannon Corporation | All rights reserved

Project Status Report

MILESTONE SYMBOL LEGEND

Kickoff | Complete | On-time | Future | Off-track | Late

Key Milestones

11.20.24	12.12.24	1.7.25	1.15.25	1.28.25	1.29.25	2.11.25	2.26.25
Board Workshop	**Steering Committee Mtg**	**Stakeholder Interviews Complete**	**Facility Tours Complete**	**Administrative Strategy Workshop**	**Board Meeting**	**Steering Committee Meeting: *Current State Review***	**Board Meeting: *Current State Review***

ACCOMPLISHMENTS OF PAST 60 DAYS

Stakeholder Interviews Completed

+ 52 Interviews (7 Executive, 45 Departmental)

Facility Assessments/Tours Completed

+ 50 Site Tours (42 Assessments, 8 Departmental)

Data

+ Current State Analysis

Meetings

+ Workplace/Admin Workgroup Meetings: 11/15, 12/6, 1/10
+ Facilities Workgroup Meetings: 11/11, 12/2, 1/13
+ Steering Committee Meetings: 11/5, 12/12
+ Board Meeting/Workshop: 11/20

GOALS FOR NEXT 30 DAYS

Stakeholder Interviews

+ Finalize summaries

Facility Assessment/Tours

+ Finalize/Validate assessment ratings

Data

+ Current State Validation
+ Align Future State Drivers

Meetings

+ Workplace/Admin Workgroup Meeting: 2/7
+ Facilities Workgroup Meeting: 2/10
+ Steering Committee Meeting: 2/11
+ Board Meeting: 2/26

KEY ACTION ITEMS FOR NEXT 30 DAYS

- ❑ **Current State Review**
- ❑ **Data Validation & Alignment**
- ❑ **Priority Area Discussions**

FOR DISCUSSION TODAY

- ❑ **Focus Area Trade Offs**

© 2025 The Cannon Corporation | All rights reserved

Review of Aspirations, Project Vision & Focus Areas



© 2025 The Cannon Corporation | All rights reserved

Prior Meeting Activity – Project Aspirations

Improve health and reduce disparities, through high quality clinical care

Foster learning through **education and training** and by providing a robust clinical training. Lead or participate in **research** and **innovation.**

Build trust through accountability, integrity, **partnerships**, and good use of resources.

Build communities and fuel economic development focusing on equity, inclusion, dignity and respect.

Give two examples that respond to each of these four questions:

Positive

→ Where is Parkland making the greatest impact now?

Optimistic

→ Where should Parkland focus and invest more?

Realistic

→ Where should Parkland focus and invest less?

Aspirational

→ What is needed to lead the way, to be exemplary?

© 2025 The Cannon Corporation | All rights reserved

Project Aspirations

1. **Access to high quality culturally competent care that is easy, convenient and timely**

2. **Deploy a fully integrated digital health strategy to support access to care**

3. **Contribute to the economic development of Dallas County and its residents**

4. **Develop payor relationships to secure sustained reimbursement and funding sources**

5. **Engage with partners to meet the complex health and social needs of the community Parkland serves**

6. **Educate, train and develop the future workforce**

© 2025 The Cannon Corporation | All rights reserved

Project Vision:

Planning Parkland's future spaces in alignment with strategy, supportive of the needs of our patients, community, and workforce

© 2025 The Cannon Corporation | All rights reserved

Focus Areas

✓ *Defining facility strategy, location, or distribution of key services at Parkland Health*

- **Ambulatory Clinic Distribution Strategy**
- **Optimize Office Space**
- **Secondary Hospital Locations**
- **Digital Health Integration, Telehealth & Virtual**
- **Cancer Program Strategy**
- **Size and Organization of Inpatient Services**
- **Parking Strategy**
- **Property/Land Strategy**
- **Impact of Southwestern Medical District Projects**
- **Dialysis Services Strategy**

© 2025 The Cannon Corporation | All rights reserved

Trade-off Activity

© 2025 The Cannon Corporation | All rights reserved

Next Steps

© 2025 The Cannon Corporation | All rights reserved

Next Steps

1	Finalize current state analytics to establish baseline and observe trends
2	Finalize facility assessment ratings
3	Develop future state demand model and resultant space needs
4	Initiate the development of strategic facility plan options

© 2025 The Cannon Corporation | All rights reserved

BLUE COTTAGE
of CannonDesign

© 2025 The Cannon Corporation | All rights reserved

CEO Update on System Operations and Board FY25Q1 Priorities Discussion

FY25 Board Priorities

January 2025

FY25 Board Priorities

TAXPAYER INVESTMENT

- Achieve ≤ 6.7 FTE per AOB FY25 **Productivity** Goal

ACCESS

- Achieve at least a 10% improvement in the median **Wait Time** for new adult patients when compared to FY24 in at least five (5) out of the seven (7) selected clinics
- Complete consulting engagement and develop **Business Continuity** Plans for priority departments by end of FY25

QUALITY

- Achieve FY25 "**Clinical Excellence**" Targets for Hospital
- Achieve FY25 "**Clinical Excellence**" Targets for Pop Health

TRUST

- Maintain or improve Press Ganey's Patient **Experience** Survey overall system metric, Likelihood to Recommend (LTR) score
- Maintain or improve Press Ganey's One Survey item, "There is a climate of **Trust** within my work unit/this hospital/clinic"
- Achieve targets for **Nursing** Inpatient and Ambulatory Areas for **Careful Listening** and **Responsiveness** questions from Press Ganey

PEOPLE

- Maintain or improve Press Ganey's One Survey **Engagement** Indicator (EI) score for Employee, Hospital and Clinic Provider groups

FACILITIES

- Achieve FY25 milestones for Strategic **Facilities** Plan

Taxpayer Investment

- Achieve ≤ 6.7 FTE per AOB FY25 **Productivity** Goal

Achieve ≤ 6.7 FTE per AOB FY25 Productivity Goal



Source: Labor Optimization and Process Improvement – January 2025

Access

- Achieve at least a 10% improvement in the median **Wait Time** for new adult patients when compared to FY24 in at least five (5) out of the seven (7) selected clinics
- Complete consulting engagement and develop **Business Continuity** Plans for priority departments by end of FY25

Achieve at Least a 10% Improvement in the Median Wait Time for New Adult Patients in at Least Five (5) Out of the Seven (7) Selected Clinics



Source: Business Sustainability – January 2025

Complete Consulting Engagement and Develop Business Continuity Plans for Priority Departments by End of FY25

119



Source: Behavioral Health Services – January 2025

Quality

- Achieve FY25 "**Clinical Excellence**" Targets for Hospital
- Achieve FY25 "**Clinical Excellence**" Targets for Pop Health

Achieve FY25 “Clinical Excellence” Targets for Hospital



Source: Quality & Safety Operations – January 2025

Achieve FY25 “Clinical Excellence” Targets for Pop Health



Source: Quality & Safety Operations – January 2025

Trust

- Maintain or improve Press Ganey's Patient **Experience** Survey overall system metric, Likelihood to Recommend (LTR) score
- Maintain or improve Press Ganey's One Survey item, "There is a climate of **Trust** within my work unit/this hospital/clinic"
- Achieve targets for **Nursing** Inpatient and Ambulatory Areas for **Careful Listening** and **Responsiveness** questions from Press Ganey

Maintain or Improve Press Ganey's Patient Experience Survey Overall System Metric, Likelihood to Recommend (LTR) Score



Source: Office of Talent Management – January 2025

Maintain or Improve Press Ganey's One Survey Item, "There is a climate of trust within my work unit/this hospital/clinic"

125



FY25 result available upon completion of One Survey.

Source: Office of Talent Management – January 2025

Achieve Targets for Nursing Inpatient and Ambulatory Areas for Careful Listening and Responsiveness Questions from Press Ganey



Source: Nursing – January 2025

People

- Maintain or improve Press Ganey's One Survey **Engagement** Indicator (EI) score for Employee, Hospital and Clinic Provider groups

Maintain or Improve Press Ganey's One Survey Engagement Indicator (EI) Score for Employee, Hospital, and Clinic Provider Groups



FY25 result available upon completion of One Survey.

Source: Office of Talent Management – January 2025

Facilities

- Achieve FY25 Milestones for Strategic **Facilities** Plan

Achieve FY25 Milestones for Strategic Facilities Plan



Source: Strategy – January 2025

Questions

Discussion Regarding Pension Funding Plan Recommendation

Consideration and Appropriate Action Regarding Fiscal 8311-1-14 Retirement Plan Investment Policy

Fiscal 8311-1-14 Retirement Plan Investment Policy

Requirements regarding this document are found in:

- The Texas Health & Safety Code 281.049

Background:

- Last published 1/23/24 (3-year approval period), but we have a new investment consulting firm and recommended asset allocation changes which necessitate changes now.

Revisions:

The Investment Committee reviewed and recommended modifications ahead of the next triennial review.

- Clarify the Investment Consultants' role regarding the Plan's investment managers (page 4)

- Replace the asset allocation target illustration for the addition of 5% private equity investments funded by reductions of public equity and 5% private credit/debt investments funded from public credit allocations (page 11) and added narratives for the new asset classes (pages 14 and 15)

- Removed a duplicative paragraph regarding investments in mortgage-backed securities (page 14)

- Clarified the exceptions for private equity and private debt under the prohibited transactions section of the Policy (page 16)

- Removed language from the Policy's diversification section that was unnecessarily broad (page 17)

- Replaced the peer group/benchmark index section for the change of investment consultants and the added asset classes (pages 19/20)

- Removed the Appendix for individual manager guidelines that was outdated and beyond the scope of the Investment Committee's responsibility to manage

- Several minor edits for clarity and grammar

Approvals:

- Joe Mayer, Treasury Director
- Rick Humphrey, EVP & CFO
- Investment Committee (1/16/25 via email)
- Board Budget and Finance Committee (scheduled 1/28/25)
- Board of Managers (scheduled 1/29/25)

8311-1-14
WD 02/08
RD-02/08/19
RD 3/31/21
RD 8/28/23
RD 1/23/24
20 Pages

PARKLAND HEALTH & HOSPITAL SYSTEM

FISCAL MANUAL

RETIREMENT PLAN INVESTMENT POLICY

DALLAS COUNTY HOSPITAL DISTRICT RETIREMENT INCOME PLAN

8311-1-14
WD 02/08
RD-02/08/19
RD 3/31/21
RD 8/28/23
RD 1/23/24
20 Pages

PARKLAND HEALTH & HOSPITAL SYSTEM

FISCAL MANUAL

RETIREMENT PLAN INVESTMENT POLICY

TABLE OF CONTENTS

PAGE

Commented [AL1]: Will update on final version

I.	**Purpose of Investment Policy**	1
II.	**Administration**	2
III.	**Asset Allocation Strategy**	9
IV.	**Investment Guidelines**	11
V.	**Performance Measurement Standards**	15
~~Appendix A~~	~~**Individual Manager Guidelines**~~	~~18~~

8311-1-14
WD 02/08
RD-02/08/19
RD 3/31/21
RD 8/28/23
RD 1/23/24
20 Pages

PARKLAND HEALTH & HOSPITAL SYSTEM

FISCAL MANUAL

RETIREMENT PLAN INVESTMENT POLICY

SECTION I

PURPOSE OF INVESTMENT POLICY

The Dallas County Hospital District dba: Parkland Health ~~& Hospital System~~ ("Parkland") maintains a defined benefit pension plan known as the Dallas County Hospital District Retirement Income Plan ("Plan") that provides retirement benefits for those Parkland employees who are eligible to participate. The Plan was initially adopted January 1, 1982 by Parkland as a replacement for Social Security benefits. The purpose of the Plan is to provide financial security to our employees after retirement. The Plan is funded by the employees through a 6.2% payroll deduction (effective January 2018; no caps or limits) on base earnings, with Parkland providing any additional funding required to meet the actuarial determined contribution as calculated by an independent actuary. Since Parkland is a political subdivision of the State of Texas, the Plan is not subject to ERISA, but is subject to State regulation through the Texas Pension Review Board and the accounting for the Plan has to comply with Government Accounting Standards Board requirements. Any changes to the Plan require approval by Parkland's Board of Managers. This Investment Policy ("Policy") defines the investment policy for assets of the Plan. This Policy sets forth administration responsibilities for the Plan and Plan assets, asset allocation strategy for the Plan, investment guidelines for Plan assets and performance measurement standards for investment of Plan assets. The objectives of this Policy are formulated in response to the following:

- the anticipated financial needs of the Plan;
- consideration of risk tolerance; and
- the need to document and communicate with the Plan's investment managers, advisors, and service providers regarding the purpose of investment policy, administration, asset allocation strategy, investment guidelines and performance measurement standards for the Plan and the Plan assets and ultimately to Plan participants.

This Policy shall apply to the following parties that have responsibilities regarding the Plan Assets:

- Parkland's Board of Managers;
- The Budget and Finance Committee of Parkland's Board of Managers;
- The Plan Investment Committee;
- The Plan Investment Consultant;
- The Plan's Investment Managers;
- The Plan's Trustee(s)/Custodian(s); and
- Parkland's staff, as contemplated by this Policy and as requested from time to time by the Investment Committee and/or the Budget and Finance Committee.
- Transition Managers

8311-1-14
WD 02/08
RD-02/08/19
RD 3/31/21
RD 8/28/23
RD 1/23/24
20 Pages

PARKLAND HEALTH & HOSPITAL SYSTEM

FISCAL MANUAL

RETIREMENT PLAN INVESTMENT POLICY

This Policy shall be reviewed annually and communicated to all the foregoing parties involved in the oversight of the Plan, together with any amendments of this Policy from time to time.

INVESTMENT OBJECTIVES

Investments will be made in the sole interest of the participants and beneficiaries of the Plan and in accordance with the following objectives:

- To ensure an adequate pool of assets to support the benefit obligations to participants, retirees and beneficiaries;
- Obtain a reasonable rate of return consistent with a prudent level of portfolio risk, while controlling costs incurred in administering and managing the assets; and
- Improvement in the Plan's funded status, providing improved benefit certainty and benefit levels for employees participating in the Plan and the opportunity to reduce employer contributions to the Plan.

SECTION II

ADMINISTRATION

The Board of Managers is responsible for ensuring that all Plan assets are managed effectively and prudently. The responsibilities of the Board's Budget and Finance Committee and other parties related to the management of the Plan assets are as follows:

A. <u>Budget and Finance Committee</u>

The Budget and Finance Committee shall have the authority and responsibility to:

- Recommend adoption of this Policy and amendments from time to time as deemed necessary, desirable or appropriate;
- Recommend appointments to the Investment Committee;
- Select and appoint experienced and qualified Investment Managers to manage all or a portion of the Plan's assets, and to remove Investment Managers from time to time as deemed necessary, desirable or appropriate; Investment Managers shall be selected from established and financially

sound organizations that have a proven and demonstrable record in managing funds with characteristics appropriate for the risk/return profile of the Plan's assets. The process for the selection of Investment Managers for the Plan will involve a disciplined approach, and will be fully documented in the Budget and Finance Committee's records; and

- Approve the hiring of a Custodian and an Investment Consultant to assist the Investment Committee and Parkland staff in implementing policy and managing the Plan

- Monitor the investments of the Plan assets, including periodic monitoring (at least quarterly) of the investment performance results and a periodic analysis and review (at least quarterly) of the overall investment portfolio of the Plan and its performance as measured by the performance measurement standards set forth in this Policy.

B. Investment Committee

The Investment Committee shall:

- Serve as experienced investment professionals to the Budget and Finance Committee;

- Be composed of members who are selected based upon their overall investment experience, including managing or supervising similar-sized investment portfolios, and their willingness to serve as community volunteers without compensation, but with reimbursement for reasonable out-of-pocket expenses incurred in accomplishing their Investment Committee-related duties;

- Be subject to indemnification related to actions taken within the scope of their duties as members of the Investment Committee, to the fullest extent allowed by applicable law;

- Recommend to the Budget and Finance Committee appropriate Investment Consultants, Investment Managers, Trustees and Custodians, mutual funds or other vendors to implement the Policy; and

- Suggest investment goals and objectives for the Plan and recommend an appropriate asset allocation strategy to be incorporated into this Policy.

C. Investment Managers

Investment Managers shall:

- Manage an investment strategy within the guidelines set forth in this policy;

- Implement selection and timing of investments within the guideline limitations in this Policy, and consistent with each Investment Manager’s stated philosophy and style;

- Supply timely written quarterly reports of investment performance results to Parkland staff and the Investment Consultant;

- Meet and/or communicate with Parkland staff, ~~and the~~ the ~~–~~Investment Committee, and the Investment Consultant as requested to review investment performance and discuss current strategy;

- Notify the Investment Committee, the Investment Consultant, the Budget and Finance Committee and Parkland staff in writing of any material deviations from the stated investment approach;

- Conduct the purchase and sale of investments in a manner designed to receive the combination of best price and execution;

- Promptly vote proxy ballots for the exclusive benefit of the Plan and in accordance with this Policy; and

- Proactively provide documentation of all relevant compliance issues to Parkland staff and the Investment Consultant within seven (7) days, including, but not be limited to, the following:

    - Regulatory reports
    - Changes in personnel
    - Changes in ownership
    - Any notices to or from the Securities and Exchange Commission ("SEC")
    - The commencement of any judicial or administrative proceedings

D. Investment Consultant

The Investment Consultant shall:

- Disclose any relationship or revenue between themselves and any candidate manager they may introduce to the plan.

- Be approved by the Budget and Finance Committee based on a recommendation by the Investment Committee.

- Assist the Investment Committee, the Budget and Finance Committee and Parkland staff in an open and competitive process to select Investment Managers and provide its rankings and recommendations for selection of Investment Managers to the Investment Committee and the Budget and Finance Committee.

- Review the performance of the Investment Managers versus their respective benchmarks and relevant peer groups; and make recommendations to the Investment Committee and Budget and Finance Committee as needed.

- Monitor the Investment Managers' style and characteristics to ensure they are running strategies consistent with the Policy.

- Review and analyze investment performance reports from the Investment Managers and prepare and deliver comprehensive quarterly reports regarding the Investment Managers' performance to the Investment Committee, Budget and Finance Committee and Parkland staff.

- Present to the Investment Committee and Parkland staff any recommended changes to this Policy.

- Assist the Investment Committee, the Budget and Finance Committee and Parkland staff with the review of capital markets, this policy, investment structure, and investment strategies.

- Periodically revisit each benchmark index for its continued appropriateness.

- Monitor the total investment portfolio for unintended risk associated with over-allocation to certain securities within asset classes, sectors, or geography that may overlap.

- Educate the Investment Committee and Parkland staff on investment issues that could impact the Plan.

- Annual review of investment management fees and comparisons with fees of other managers with similar strategies.

E. Trustee/Custodian

The trustee/custodian shall:

- Be a reputable, well-established, financially sound financial institution that is recognized as an industry leader. The trustee/custodian shall be approved by the Budget and Finance Committee based on a recommendation by the Investment Committee.

- Fulfill all fiduciary duties required of a trustee/custodian by pertinent state and federal laws and regulations.

- Safe keep the Plan's assets in accordance with the Trust Agreement.

- Supply timely reports of transactions and valuations of Plan assets.

F. Staff

Parkland staff shall:

- Implement the decisions of the Budget and Finance Committee and the Investment Committee.
- Review asset allocation on an ongoing basis and initiate portfolio rebalancing pursuant to parameters in this Policy.
- Coordinate communications between the Investment Committee and the Budget and Finance Committee.
- Organize Investment Committee meetings and distribute materials related to the meetings.
- Coordinate review and execution of legal documents related to the Plan's investment and administration.

Formatted: List Paragraph, Left, Tab stops: Not at 0.31"

G. Transition Manager

Transition management is the cost effective and efficient portfolio restructuring of institutional assets from single or multiple investment managers/asset classes to a new investment allocation over a short-term investment horizon. During the transition process, the transition manager is looked upon as a discretionary caretaker of the portfolio(s) to be liquidated and as the conduit for the funding of the target portfolio(s). The responsibilities of a transition manager should include the following responsibilities.

- Transition management (portfolio transition) services from the legacy portfolio(s) to the target portfolio(s).
- The transition manager will act as a fully-discretionary fiduciary and will perform the transition with utmost care and prudence. The fund sponsor realizes that markets fluctuate and risks are inherent during the transition period. However, market forces do not absolve the transition manager from negligence and applying the highest level of care and prudence inherent in a fiduciary.

- Minimize tracking error and maintain asset class (benchmark) exposure. During the transition period, the preservation of capital must be taken into consideration through the expert use of all sources of liquidity, namely: in-kind transfers ("cherry picking" of the legacy portfolio for the target portfolio), internal and external crossing networks, primary exchanges, non-displayed liquidity, and principal trades. The strategic and tactical deployment of cash, futures, ETFs, and other hedging strategies are included in the tools required to accomplish a smooth transition.

- Before the transition, the transition manager should provide the fund sponsor a written portfolio transition (liquidation) strategy, including the timeframe required, to achieve the desired objective of liquidating the legacy portfolio(s) and building (and/or funding) the target portfolio(s).

- During the transition period, daily reporting of all trade activity from commencement of the liquidation to the completion and full funding of the target portfolios should be available to Parkland.

- After the completion of the transition, the transition manager should provide Parkland with a report on the outcome and results of the transition. The report should include relevant statistics (i.e., tracking error, costs, VWAPs, t-standard, etc.) and full trading/transaction reports.

- Coordination of the firm's trading activity with investment managers (both legacy and target portfolios) and the custodial bank.

- The transition manager must carry the appropriate coverage for errors and omissions and professional liability insurance.

Formatted: List Paragraph, Left, Indent: Left: 0", First line: 0", Tab stops: Not at 0.31"

Conflicts of Interest

To avoid conflicts of interest, all members of the Investment Committee, the Budget and Finance Committee, Parkland staff and the Investment Consultant shall agree to adhere, and shall adhere, to Parkland's conflict of interest policies.

Investment Manager Selection Parameters

The following parameters articulate the general criteria used to select Investment Managers. All or part of these criteria may be employed in choosing an Investment Manager.

- At the time of engagement, investment managers will affirm that they act in a fiduciary capacity towards the Plan and its participants.
- The Investment Manager must have an investment philosophy that is clearly defined.
- The Investment Manager must demonstrate that the broader organization and investment team have been stable and have committed the resources to maintain the success of its strategy.
- An Investment Manager should have sufficient assets under management relative to the particular asset class and the placement size being awarded.
- An Investment Manager should have been managing the particular investment strategy chosen for at least three years prior to being retained by the Plan. This parameter can be waived if the Investment Manager has had experience with a comparable firm or strategy during that three-year time period.
- The Investment Manager's fee schedule should be reasonable in comparison to the relevant investment universe.

Formatted: List Paragraph, Left

Formatted: List Paragraph, Left

Formatted: List Paragraph, Left

Formatted: List Paragraph, Left

Formatted: List Paragraph, Left

Other prudent criteria may be used by the Investment Committee and the Budget and Finance Committee to select investment options, as deemed necessary.

Investment Manager Watch List Process

The Investment Consultant and/or the Investment Committee may recommend that an Investment Manager be placed on a "Watch List" if concerns develop regarding some aspect of the Investment Manager or its performance. Given that these concerns may or may not be of sufficient importance to justify termination of the Investment Manager, the Watch List is intended to serve as a management tool for the Investment Consultant and the Investment Committee to evaluate the Investment Manager. The Investment Committee may place an Investment Manager on the Watch List for any of the following reasons:

a. The Investment Manager has not met its performance standards for a sustained period.

b. The Investment Manager has changed key professionals responsible for the management of the strategy, or such change appears imminent.

c. The Investment Manager has had a significant change in ownership or control.

d. The Investment Manager has changed investment focus or has experienced style drift, departing materially from the investment objectives or parameters previously represented.

e. Judicial or administrative proceedings have been commenced that involve the Investment Manager.

f. The Investment Manager has violated, or received notice of a violation of, an SEC rule or regulation.

g. Other criteria, as determined by the Budget and Finance Committee, the Investment Committee and the Investment Consultant.

Formal Investment Manager Review

When an Investment Manager has been placed on the Watch List, the Investment Committee, in conjunction with the Investment Consultant, shall review the Investment Manager's operations and performance, and the Investment Committee and the Investment Consultant shall make any recommendations about the Investment Manager to the Budget and Finance Committee.

Upon completion of the review, the Budget and Finance Committee may (i) retain the Investment Manager, (ii) reduce the assets under management by the Investment Manager or (iii) terminate the Investment Manager and transfer the assets to a temporary index vehicle or a new Investment Manager.

SECTION III

ASSET ALLOCATION STRATEGY

The Budget and Finance Committee is guided by the philosophy that asset allocation is the most significant determinant of long-term investment return. Asset allocation targets shall be established by

the Budget and Finance Committee to achieve the total return objectives of the Plan within acceptable risk levels, as considered on a prospective basis.

The Investment Consultant will be responsible for providing asset class education and the necessary tools and analysis to enable the Investment Committee and Parkland's staff to make prudent recommendations to the Budget and Finance Committee, and to enable the Budget and Finance Committee to make prudent decisions, regarding the selection of asset classes, a strategic asset allocation, and allowable minimum and maximum ranges. When requested by the Investment Committee, Budget and Finance Committee, and/or Parkland staff an asset allocation study will be conducted by the Investment Consultant. The asset allocation strategy will be reviewed at least annually and any changes to the strategy may or may not require an asset allocation study.

The asset structure is designed to reflect a proper balance of the Plan's need for total return and the risk tolerance established by the Budget and Finance Committee.

The Budget and Finance Committee determined, based on extensive work done by the Investment Consultant and recommendations by the Investment Committee, that the Plan's desired investment objective has a strong probability of being achieved with an acceptable level of risk if the Plan invests in the Asset Classes as described on the following page.

8311-1-14
WD 02/08
RD-02/08/19
RD 3/31/21
RD 8/28/23
RD 1/23/24
20 Pages

PARKLAND HEALTH & HOSPITAL SYSTEM

FISCAL MANUAL

RETIREMENT PLAN INVESTMENT POLICY

~~Asset Class~~	~~Strategic Target~~	~~Allowable Range~~
~~Total U.S. Equity~~	~~36%~~	~~31% – 41%~~
~~Large Cap Domestic Equity~~	~~26.7%~~	~~22.7% – 30.7%~~
~~Small/Mid Cap Domestic Equity (Growth & Value)~~	~~9.3%~~	~~6.3% – 12.3%~~
~~Total Non-U.S. Equity~~	~~24%~~	~~19% – 29%~~
~~Non-U.S. Equity~~	~~16%~~	~~12% – 20%~~
~~Non-U.S. Small Cap Equity~~	~~4%~~	~~2% – 6%~~
~~Emerging Market Equity~~	~~4%~~	~~2% – 6%~~
~~Total Fixed Income~~	~~30%~~	~~26% – 34%~~
~~Core Fixed Income~~	~~20%~~	~~16% – 24%~~
~~Core Plus Fixed Income~~	~~10%~~	~~8% – 12%~~
~~Private Real Estate~~	~~10%~~	~~7% - 13%~~

Asset Class	Strategic Target (%)	Allowable Range
Growth		
US Large Cap	24	18-30
US Mid Cap	4	2-6
US Small Cap	4	2-6
Dev. Market Equity (non-US)	15	12-18
Developed Market Small Cap	4	2-6
Emerging Market Equity	4	2-6
Private Equity	5	0-8
Income Assets		
Private Debt	5	0-8
Risk Mitigating Assets		
Investment Grade Bonds	25	20-30
Diversifiers		
Real Estate	10	7-13

~~Within the Small/Mid Cap Domestic Equity Asset Classes, funds will be divided between growth and value style Investment Managers as recommended by the Investment Committee and determined by the Budget and Finance Committee.~~ Exposure of the total Plan assets to cash equivalents on average should not exceed 5% of the total Plan's value on a market value basis. Each Investment Manager's portfolio should reflect the guidelines established for that particular Asset Class. Cash exposure may drop to zero at the discretion of the Investment Manager.

Rebalancing Policy

One essential component of a strategic asset allocation policy is the development and use of rebalancing ranges for the target allocation. The Budget and Finance Committee and Investment Committee believe that systematic rebalancing should reduce portfolio volatility and increase portfolio return over the long term. The ranges specified in the table above are a function of the expected volatility of each asset class and the proportion of the total fund allocated to the asset class.

If the Plan experiences positive cash flow (*i.e.*, contributions exceed disbursements), the Plan's assets shall be rebalanced by directing new contributions to the under-allocated assets. If the Plan experiences negative cash flow, funds to make distributions will be withdrawn from over-allocated assets. If the Plan's cash flow is not sufficient to keep the allocation within the defined ranges stated above, then purchase or sale transactions are required.

The Budget and Finance Committee is charged with the responsibility of monitoring the asset allocation policy. In order to adhere to a systematic rebalancing policy, the Budget and Finance Committee delegates' authority to Parkland staff to follow and execute the asset allocation and rebalancing policy described in this Policy. The Investment Committee and the Investment Consultant will monitor the asset allocation on a quarterly basis at a minimum.

SECTION IV

INVESTMENT GUIDELINES

All investments shall be made solely in the interest of beneficiaries of the Plan, and for the exclusive purposes of providing benefits to such beneficiaries and defraying the reasonable expenses of administering the Plan.

All Plan assets should be properly diversified to reduce the potential of a single security or single sector of securities having a disproportionate or significant impact on the Plan.

8311-1-14
WD 02/08
RD-02/08/19
RD 3/31/21
RD 8/28/23
RD 1/23/24
20 Pages

RETIREMENT PLAN INVESTMENT POLICY

Where institutional mutual or commingled funds (including index funds) are used, it is expected that the investments generally conform to these guidelines described below, though the Budget and Finance Committee recognizes that the prospectus or guidelines of the fund supersede those of the Plan. On a quarterly basis, the Investment Managers shall review their investments for compliance with these guidelines. If the investments differ from these guidelines in any material respect, the Investment Manager shall notify the Plan in writing. At least one Investment Manager shall be selected to manage an Asset Class. ~~All Investment Managers shall comply with the Investment Manager guidelines included in Appendix A.~~

If there is any question regarding these guidelines and the authorization granted to purchase and/or hold a security because of its issuer, type, effective duration, or effective credit quality, the Investment Manager must consult with the Budget and Finance Committee and its Investment Consultant prior to purchase of the security.

The Budget and Finance Committee has established, based on recommendations by the Investment Committee and the Investment Consultant, the following Asset Classes as appropriate investment strategies for Plan Assets. The Budget and Finance Committee may, from time to time, modify this list based on, among other things, recommendations from the Investment Committee and/or the Investment Consultant:

- Domestic Equities
- Non-U.S. Equities
- Private Equity
- Fixed Income Securities and Cash Equivalents
- Private Debt
- Private Real Estate

A. Domestic Equities

Domestic equities shall be restricted to securities of companies that are actively traded on major U.S. exchanges. Equity holdings may also include American Depositary Receipts (ADRs), Exchange-Traded Funds (ETFs), mutual funds registered under the Investment Advisers Act of 1940 and publicly traded partnerships (such as master limited partnerships) traded on U.S. exchanges. Preferred and convertible preferred stocks may be held. Publicly traded Real Estate Investment Trust (REITs) shares may be held and are considered part of the allocation to equities.

Futures and options can be used as a substitute for equity securities provided that they are at least 100% collateralized by high quality, low volatility fixed income securities and therefore do not represent leveraging of the assets.

B. Non-U.S. Equities

The majority of non-U.S. equity holdings shall be securities issued by companies headquartered in countries included in the MSCI All Country World ex-U.S. Index (ACWI ex-U.S.). Issues may be purchased and sold on exchanges in other countries that offer a ready market for individual issues and have no restrictions on the transfer of funds to and from the U.S.

Managers holding foreign currency denominated securities are permitted to employ currency hedging strategies.

C. Private Equity

Given the unique characteristics of private equity strategies, the Investment Committee shall adopt a Private Markets Strategic Plan to govern the selection, monitoring, performance reporting and guidelines of these strategies. The Private Markets Strategic Plan shall be reviewed annually for appropriateness and shall also include a pacing plan to guide allocation decisions.

D~~C~~. Fixed Income

Fixed income investments shall be marketable securities, which may include, but not necessarily be limited to U.S. Treasury, Federal Agencies and U.S. Government guaranteed obligations, and corporate issues. Mortgage pass-throughs, and non-dollar denominated bonds may also be held. Fixed income may include opportunistic or strategic allocations to High Yield, Non-U.S. and/or Emerging Market Debt securities at the discretion of the Investment Manager. Fixed Income managers may utilize ETFs, mutual funds registered under the Investment Advisers Act of 1940, commingled vehicles or separate accounts for managing their investments.

Foreign currency fixed income holdings are restricted to investment grade securities of issuers in countries represented in the Citigroup World Government Non-U.S. Bond Index. Foreign currency securities must be actively traded in major markets.

~~Mortgage backed securities held should exhibit price, volatility, and liquidity similar to components of the Bloomberg U.S. Mortgage Backed Securities Index. The intent is to invest only in the most conservative mortgage instruments issued by the Federal National Mortgage Association, Federal Home Loan Mortgage Corporation and Government National Mortgage Association.~~

Privately placed fixed income issues may be held if the credit risk is carefully evaluated and judged to conform to this Policy, and there is a secondary market for potential sale before maturity or call date.

In addition to the securities outlined above, the following securities are considered permissible for a fixed income manager, but only if specifically stated in the individual manager's guidelines:
Municipal Securities, Convertible Bonds, Collateralized Mortgage Obligations (CMO), Commercial Mortgage-Backed Securities (CMBS), Asset-Backed Securities (ABS), and Residential Mortgage-Backed Securities (RMBS).

If an Investment Manager has any questions about the authorization granted to purchase and/or hold a security because of its issuer, type, effective duration, or effective credit quality, the manager must consult with Parkland staff prior to purchase of the security.

The duration of each fixed income portfolio should not exceed 150% of the Bloomberg U.S. Aggregate Bond Index duration.

The weighted average credit quality of the portfolio will not fall below BBB- or equivalent. No more than 5% of the fixed income portfolio, at time of purchase, may be invested in issuances of any one company or entity, except for government or agency issues.

E. Private Debt

Given the unique characteristics of private debt strategies, the Investment Committee shall adopt a Private Markets Strategic Plan to govern the selection, monitoring, performance reporting and guidelines of these strategies. The Private Markets Strategic Plan shall be reviewed annually for appropriateness and shall also include a pacing plan to guide allocation decisions.

F. Cash Equivalents

Cash equivalent reserves shall consist of cash instruments having a quality rating by at least one rating agency of A-1, P-1 or higher with an average maturity of 90 days or less.

G. Private Real Estate

Private real estate investments may be made ~~through direct property ownership, or~~ indirectly through such vehicles as joint ventures, general or limited partnerships, limited liability companies, private REITs~~S~~, private mortgage loans (but not publicly traded mortgage securities) and other loans including

mezzanine debt, or interests in companies or entities that directly or indirectly hold real estate or real estate interests, or other open-end commingled fund structures.

This Asset Class should be broadly diversified, investing primarily in existing, majority leased income-producing properties with strong cash flows that are expected to increase over time, providing potential for capital appreciation. Ownership should primarily be through equity interest with the use of leverage being limited to no more than 40% of the total assets in this Asset Class. This Asset Class should also be diversified by property types with investments in office, residential, retail, industrial, hotel and self-storage properties and by the various geographic regions of the country.

Prohibited Transactions

The following securities and transactions are not authorized without a written request that sets forth a detailed explanation and recommendation from the Investment Manager and that receives the prior written approval from the Investment Committee, except that the following prohibitions shall not apply to Investment Managers for the Private Equity, Private Debt, or Private Real Estate Asset Classes:

a. Collateralized debt obligations;

b. Letter stock and other unregistered equity securities;

c. Commodities or commodity contracts (except for unleveraged stock or bond index futures and currency futures and options);

d. Short sales, warrants or margin transactions; or any leveraged investments;

e. Venture capital partnerships or other private equity investments.

f. Bonds or other financial instruments issued by the Dallas County Hospital District or its affiliates.

Any financial options and futures employed must be primarily for defensive and hedge strategies undertaken to preserve principal. They may also be used as a substitute for the underlying security, providing there is no leverage.

Diversification

Investments shall be diversified with the intent to minimize the risk of large losses. Consequently, the total portfolio will be constructed and maintained to provide prudent diversification with regard to the concentration of holdings in individual issues, corporations or industries.

~~Not more than 5% of the total stock portfolio valued at market may be invested in the common stock of any one corporation. Not more than 25% of the total stock portfolio valued at market may be held in any one sector as defined by the Plan's Investment Consultant.~~

~~With the exception of securities issued by the U.S. Government and its agencies, no single fixed income issue will represent more than 5% of the total fixed income portfolio as measured by market value.~~

SECTION V

PERFORMANCE MEASUREMENT STANDARDS

The most important performance standard is the achievement of long-term investment results consistent with this Policy. The asset allocation P~~p~~olicy will be the primary determinant of return over time. Implementation of this Policy will be directed toward achieving this standard with an acceptable level of risk measured by standard deviation.

Performance measurement standards are required for determining whether or not the Plan's goals are being met. They also provide an objective basis for evaluating how well individual Investment Managers perform and how they complement each other and add value collectively. The performance measurement standards will be used as the benchmarks against which results will be measured and evaluated; however, it is understood there is no guarantee that such results will be achieved.

There are performance measurement standards for the aggregate of the Plan assets as well as for each Asset Class and Investment Manager.

8311-1-14
WD 02/08
RD-02/08/19
RD 3/31/21
RD 8/28/23
RD 1/23/24
20 Pages

RETIREMENT PLAN INVESTMENT POLICY

AGGREGATE PLAN ASSET PERFORMANCE MEASUREMENT STANDARDS

While keeping in mind the actuarial return assumptions of the Plan, the aggregate of the Plan's assets will be managed with the goal of achieving the following over a five-year period:

- An annualized rate of return, net of management fees, that meets the actuarial assumed return as determined by the Plan's actuary;
- A return, net of management fees, that outperforms a hypothetical portfolio composed of indices weighted according to the target allocation as mutually determined by the Investment Committee and Investment Consultant; and
- Comparable volatility of returns, as measured by the standard deviation of quarterly returns of the benchmark index as calculated by the Investment Consultant.

The return on the aggregate of the Plan's assets will periodically be compared to a weighted average composite of the asset class benchmarks and a universe of other public retirement income plans.

INVESTMENT MANAGERS

To ensure that results of Investment Managers are fairly evaluated, the Investment Committee and the Budget and Finance Committee will use the following comparative performance statistics for actively managed products. The performance of the strategy managed by each Investment Manager will be expected to achieve minimum performance standards as follows and as set forth in the chart below. Active managers should:

a. Rank in the top 50% of an appropriate peer group of actively managed portfolios (as indicated below);

b. Meet or exceed an appropriate benchmark index (as indicated below), net of management fees;

c. Maintain a risk level, as measured by the standard deviation of quarterly returns, which is comparable to that of the appropriate benchmark index, as indicated below. To the extent that the Investment Manager takes more/less risk than the market and/or the appropriate peer group, returns are expected to increase/decrease commensurately; and

~~d. Meet the Individual Manager Guidelines set forth in Appendix A.~~

PARKLAND HEALTH & HOSPITAL SYSTEM

FISCAL MANUAL

RETIREMENT PLAN INVESTMENT POLICY

These performance measurement standards should be achieved over three-year periods. Although failure to achieve these performance measurement standards will not result in the automatic termination of an Investment Manager, the Investment Committee and the Budget and Finance Committee shall review any Investment Manager that fails to achieve the standards and shall document its reasons for retaining the Investment Manager and such manager will be placed on a watch list.

The specific peer groups and benchmarks for each Asset Class are detailed here:

Commented [AL2]: Updated to match existing reporting and reflect the removal of the custom Callan peer groups

Asset Class	**Peer Group** *Exceed 50th Percentile*	**Benchmark Index** *Outperform* *Net of Investment Fees*
U.S. Equity	~~*Callan Public Find Domestic Equity*~~	*Russell 3000 Index*
Large Cap Core (Passive)	~~*N/A*~~*eV US Large Cap Equity*	S&P 500 +/- 10 basis points
Small/Mid Cap Value Equity	*eV US Small-Mid Cap Value Equity* ~~*Callan Small/Mid Cap Value Peer Group*~~	Russell 2500 Value
Small/Mid Cap Growth Equity	*eV US Small-Mid Cap Growth Equity*~~*Callan Small/Mid Cap Growth Peer Group*~~	Russell 2500 Growth
Non-U.S. Equity	~~*Callan Public Fund Non-US Equity*~~	MSCI ACWI ex-US IMI
Non-U.S. Equity	*eV EAFE Equity* ~~*Callan Non-U.S. Equity Peer Group*~~	MSCI EAFE (net) ~~or ACWI ex-US (net) Depending on the Manager~~
Non-U.S. Small Cap Equity	*eV ACWI ex-US Small Cap Equity*~~*Callan International Small Cap Peer Group*~~	MSCI EAFE Small Cap or World ex-US Small Cap (net)~~World ex-US Small Cap (net)~~
Emerging Market Equity	*eV Emerging Markets Equity*~~*Callan Emerging Markets Equity Database*~~	MSCI Emerging Markets (net)
Private Equity	*n/a*	MSCI ACWI +2% 1Qtr lagged
Private Real Estate	~~*Callan Real Estate Open End Peer Group*~~	NFI-ODCE Equal Weight Net
Fixed Income	~~*Callan Public Fund Domestic Fixed Income*~~	Bloomberg US Aggregate
Core Fixed Income	*eV US Core Fixed Income*~~*Callan Core Bond Fixed Income Peer Group*~~	Bloomberg US Aggregate

Core Plus Fixed Income	*eV US Core Plus Fixed Income~~Callan Core Bond Plus Peer Group~~*	Bloomberg US Aggregate
Private Debt	n/a	50% Credit Suisse Leveraged Loan Index + 50% Bloomberg US High Yield + 1% 1 Qtr lagged

~~***APPENDIX A***~~

~~***INDIVIDUAL MANAGER GUIDELINES***~~

~~The Individual Manager Guidelines are in addition to the Investment Guidelines and Performance Measurement Standards set forth in the Investment Policy. Manager Guidelines are included for separate accounts. Mutual funds and commingled funds should follow the guidelines established by the Investment Manager.~~

~~***APPENDIX A***~~

~~***INDIVIDUAL MANAGER GUIDELINES***~~

Commented [LF3]: Consider removing the guidelines, as each time you change a manager you need to update the IPS. They can live elsewhere, preferably not in the IPS...

~~**Allspring**~~
~~**Fundamental Small/Mid Cap Growth Equity**~~

~~**Investment Strategy:**~~ ~~The Fundamental Small-to-Mid-Cap Growth equity strategy is focused on bottom-up research striving to identify companies with strong business models and attractive growth fundamentals. A heavy emphasis is placed on proprietary in-house research. Investments are made solely on the fundamentals of each investment with a strict valuation overlay.~~

~~**Primary Benchmark:**~~
- ~~Russell 2500 Growth Index.~~

~~**Return Expectations:**~~
- ~~Rank in the top 50% of the eV US Small-Mid Cap Growth Equity Callan Small/Mid Cap Growth Peer Group.~~
- ~~Exceed the Primary Benchmark (after fees) over 3-year time periods.~~

~~**Risk Expectations**:~~
- ~~Risk-adjusted performance measured by Sharpe Ratio that ranks above median versus the eV US Small-Mid Cap Growth EquityCallan Small/Mid Cap Growth Peer Group.~~

PARKLAND HEALTH & HOSPITAL SYSTEM

FISCAL MANUAL

RETIREMENT PLAN INVESTMENT POLICY

- ~~Comparable to the Primary Benchmark over 3-year time periods.~~

~~Cash Holdings~~

- ~~On average, at least 95% of the investment account assets will be invested in equity or equity related securities. Cash reserves should not exceed 15% of portfolio assets. Exceptions are allowed when building liquidity in anticipation of a large withdrawal or by special permission from the Investment Committee.~~

~~Non-U.S. Holdings~~

- ~~Equity holdings may include non-U.S. securities, including American Depositary Receipts (ADRs), all of which must be traded on a U.S. stock exchange and be dollar-denominated. Non-U.S. securities may not exceed 20% at market value.~~

~~Equity Diversification~~

- ~~Current market value of a single security cannot exceed 6% of the portfolio at market value. Any individual Sector weight should generally not exceed 40%. To exceed these limits, a request must be made to the Investment Committee.~~

8311-1-14
WD 02/08
RD-02/08/19
RD 3/31/21
RD 8/28/23
RD 1/23/24
20 Pages

PARKLAND HEALTH & HOSPITAL SYSTEM

FISCAL MANUAL

RETIREMENT PLAN INVESTMENT POLICY

~~***APPENDIX A***~~

~~***INDIVIDUAL MANAGER GUIDELINES***~~

~~**LSV Asset Management**~~
~~**Small/Mid Cap Value Equity**~~

~~**Investment Strategy:**~~	~~LSV Asset Management's investment philosophy is that superior long-term results can be achieved by systematically exploiting the judgmental biases and behavioral weaknesses that influence the decisions of many investors. Their security selection process is quantitative.~~
~~**Primary Benchmark:**~~	~~• Russell 2500 Value Index.~~
~~**Return Expectations:**~~	~~• Rank in the top 50% of the eV US Small-Mid Cap Value EquityCallan Small/Mid Cap Value Peer Group.~~ ~~• Exceed the Primary Benchmark (after fees) over 3-year time periods.~~
~~**Risk Expectations:**~~	~~• Risk-adjusted performance measured by Sharpe Ratio that ranks above median versus the eV US Small-Mid Cap Value EquityCallan Small/Mid Cap Value Peer Group.~~ ~~• Comparable to the Primary Benchmark over 3-year time periods.~~
~~**Cash Holdings**~~	~~• On average, at least 95% of the investment account assets will be invested in equity or equity-related securities. Cash reserves should not exceed 15% of portfolio assets. Exceptions are allowed when building liquidity in anticipation of a large withdrawal or by special permission from the Investment Committee.~~
~~**Non-U.S. Holdings**~~	~~• Equity holdings may include non-U.S. securities, including American Depositary Receipts (ADRs), all of which must be traded on a U.S. stock exchange and be dollar-denominated. Non-U.S. securities may not exceed 10% at market value.~~
~~**Equity Diversification**~~	~~• Current market value of a single security cannot exceed 5% of the portfolio at market value. Any individual Sector weight should generally not exceed 35%. To exceed these limits, a request must be made to the Investment Committee.~~

8311-1-14
WD 02/08
RD-02/08/19
RD 3/31/21
RD 8/28/23
RD 1/23/24
20 Pages

PARKLAND HEALTH & HOSPITAL SYSTEM

FISCAL MANUAL

RETIREMENT PLAN INVESTMENT POLICY

~~***APPENDIX A***~~

~~***INDIVIDUAL MANAGER GUIDELINES***~~

~~**Income Research + Management**~~
~~**IR+M Aggregate Core Fixed Income**~~

~~**Investment Strategy:**~~

- ~~Maintain duration neutral position (+/- 10% of Index).~~
- ~~Overweight spread sectors when compensated to do so.~~
- ~~Scour niche markets that can offer structural and price advantages.~~
- ~~Carefully select what Income Research & Management believes are the most attractive diversified set of bonds in the investment grade universe.~~
- ~~Incorporate Income Research + Management's best ideas in meaningful position sizes in all appropriate portfolios.~~

~~**Primary Benchmark:**~~

- ~~Bloomberg U.S. Aggregate Bond Index.~~

~~**Return Expectations:**~~

- ~~Rank in the top 50% of the eV US Core Fixed IncomeCallan Core Bond Fixed Income Peer Group.~~
- ~~Exceed the Primary Benchmark (after fees) over 3-year time periods.~~

~~**Risk Expectations:**~~

- ~~Risk-adjusted performance measured by Sharpe Ratio that ranks above median versus the eV US Core Fixed IncomeCallan Core Bond Fixed Income Peer Group.~~
- ~~Comparable to the Primary Benchmark over 3-year time periods.~~

~~**Issuer Concentration:**~~

- ~~With the exception of US Treasury, US Agency, securities guaranteed by the full faith and credit of the US Government, and other sovereign-issued debt, no more than 5% of the portfolio may be invested in the securities of a single issuer. Plan investments in debt or other obligations of the plan sponsor are prohibited.~~

~~**Credit Quality:**~~

- ~~The weighted-average quality of the portfolio shall be maintained at a minimum quality of AA- at all times.~~

- ~~At least ninety percent of the portfolio shall be invested in fixed-income securities with a quality rating of investment grade by Moody's, Fitch or Standard & Poor's at the time of purchase. Up to ten percent of the portfolio at the time of purchase may be invested in securities with a quality rating of below investment grade or may be unrated.~~

8311-1-14
WD 02/08
RD-02/08/19
RD 3/31/21
RD 8/28/23
RD 1/23/24
20 Pages

PARKLAND HEALTH & HOSPITAL SYSTEM

FISCAL MANUAL

RETIREMENT PLAN INVESTMENT POLICY

Parkland

Parkland Investment Committee Report

Dallas County Hospital District
Parkland Health
January 2025

Parkland

Defined Benefit Plan

- Asset Balance – As of September 30, 2024, the market value of Pension Plan assets was $1.904 billion, a $125 million increase for the quarter.
- Asset Allocation - All asset classes were within their strategic target ranges at the end of the quarter.
- Performance - The Plan generated a 6.1% net return during the quarter with a Policy Index of 5.8%. For the trailing 12 months, the Plan generated returns of 20.2% as compared to the Policy Index of 20.8%.
- Performance details of all managers are provided in the Appendix.

Parkland

Defined Contribution Plan

- Plan assets increased by $90 million to $1.60 billion as of September 30, 2024.
- Target date funds make up 46% of the Plan's assets, the stable value fund represents 11% of assets and investments in the five core funds form the balance.
- Performance for the Plan's investment funds is summarized in the Appendix.

Parkland

Other Business

- The group reviewed investment management and administrative fees for both plans and determined that costs were in line with the market.
- The Defined Benefit Plan's core plus fixed income manager, Western Asset Management Company (WAMCO), is under investigation for manipulating investor income. WAMCO's performance has been below the benchmark for more than a year. The Committee agreed to move the Plan's WAMCO fund holdings to an index fund at Mellon Investments. With this change, Mellon has agreed to lower its 2 basis point fee on the Plan's S&P 500 index fund and the 8 basis point fee on the emerging market equity index fund to 0.7 basis points for all three index funds.
- Following the December 18, 2024 presentation on private equity and private credit investing to the Parkland Board of Managers, management requested that an updated Defined Benefit Plan investment policy be delivered to Budget & Finance to consider in their January 28, 2025 meeting.

Parkland

Other Business

- The group also reviewed funds available for direct investment by participants in the Defined Contribution Plan and agreed that the Plan would benefit from the addition of several index funds with lower fee structures. The Committee also agreed to replace the current S&P 500 index fund managed by Schwab for a consistent lineup of index funds. The recommended additions/changes are:

Fund	Description	Benchmark	Mgmt Fee
Fidelity Extended Market Index Fund	SMID cap blend US equity	Dow Jones US Completion	3.5 bps
Fidelity Global ex US Fund	Non-US large cap blend	MSCI ACWI ex US	5.5 bps
Fidelity U.S. Bond Index Fund	Bond index fund	Bloomberg Agg	2.5 bps
BlackRock LifePath Index 2065 K	Add a TDF age sleeve	Blackrock Lifepath 2065 custom	9 bps
Fidelity 500 Index Fund	Replace Schwab's S&P Fund	S&P 500	1.5 bps

- The Committee Chair, Ryan Bailey, agreed to stay on the Committee for another three-year term if approved by the Board.

Parkland

Action Items

- The Investment Committee requests approval of the revised Investment Policy Statement for the Defined Benefit Plan.

- The Investment Committee recommends approval of Ryan Bailey to serve on the Committee for another three-year term.

Parkland

Appendix

Parkland Investment Committee Update

Defined Benefit Plan: Q3 Asset Allocations and Performance



Total Plan	**1,904,942,063**	**100.0**	**6.1**	**11.3**	**20.2**	**3.8**	**7.6**	**6.7**	**5.9**	**Jan-07**
Policy Benchmark			*5.8*	*11.6*	*20.8*	*4.3*	*7.9*	*6.8*	*6.1*	

Parkland

Defined Benefit Plan
Q1 Performance 2024

Strategy	Manager	Net Return	Benchmark	Index
Large Cap Equity	Mellon Capital S&P 500 Index	6.0%	5.8%	S&P 500
Small/Mid Cap Value	LSV Asset Mgmt	8.6%	9.6%	Russell 2500 Value
Small/Mid Cap Growth	Allspring Capital Mgmt	8.3%	7.0%	Russell 2500 Growth
International Equity	MFS International Equity	8.2%	7.3%	MSCI EAFE
International Equity	Dodge & Cox	10.0%	7.3%	MSCI EAFE
International Equity	Acadian International Small Cap	7.3%	10.4%	MSCI World ex U.S. Small Cap
International Equity	Xponance International Small Cap	6.3%	10.4%	MSCI World ex U.S. Small Cap
Emerging Mkt Equity	Genesis	8.3%	8.7%	MSCI Emerging Mkts
Emerging Mkt Equity	Mellon Investments Index	8.3%	8.7%	MSCI Emerging Mkts
Core Fixed Income	Income Research and Management	4.9%	5.2%	Bloomberg Aggregate
Core + Fixed Income	Western Asset Management	5.4%	5.2%	Bloomberg Aggregate
Real Estate	Heitman - American Real Estate Trust	0.2%	0.0%	NCREIF-ODCE Value
Real Estate	JPMorgan - Strategic Property Fund	0.8%	0.0%	NCREIF-ODCE Value
Cash	Mellon EB TIF	1.3%	1.4%	90 Day U.S. Treasury Bill

Defined Contribution Plan
Q3 Asset Allocations 2024

Current Plan Allocation



Asset Allocation	09/30/2024 Market Value($)
Tier I	727,810,356
Tier II	438,355,562
Tier III	414,978,985
Tier IV	19,793,971
Total	1,600,938,873

Tier I	Target Date Funds
Tier II	Passive/Index Funds
Tier III	Core/Direct Market Funds
Tier IV	Stable Value Fund

Parkland

Defined Contribution Plan Q1 Performance 2024

No.	Strategy	Manager	Return	Benchmark	Index
1	Target Date	BlackRock LifePath Index Retire	5.8%	5.8%	BR LifePath Index Retired CB
3	Target Date	BlackRock LifePath Index 2025	5.9%	5.9%	BR LifePath Index 2025 CB
4	Target Date	BlackRock LifePath Index 2030	6.3%	6.3%	BR LifePath Index 2030 CB
5	Target Date	BlackRock LifePath Index 2035	6.6%	6.7%	BR LifePath Index 2035 CB
6	Target Date	BlackRock LifePath Index 2040	6.8%	6.9%	BR LifePath Index 2040 CB
7	Target Date	BlackRock LifePath Index 2045	7.0%	7.2%	BR LifePath Index 2045 CB
8	Target Date	BlackRock LifePath Index 2050	7.1%	7.3%	BR LifePath Index 2050 CB
9	Target Date	BlackRock LifePath Index 2055	7.1%	7.3%	BR LifePath Index 2055 CB
10	Target Date	BlackRock LifePath Index 2060	7.1%	7.3%	BR LifePath Index 2060 CB
11	Domestic Equity	Schwab S&P 500	5.9%	5.9%	S&P 500
12	Domestic Equity	AB Discovery Value Fund	7.6%	9.6%	Russell 2500 Value
13	Domestic Equity	RBC SMID Cap Growth Fund	5.6%	7.0%	Russell 2500 Growth
14	International	American Funds EuroPacific	5.4%	8.2%	MSCI ACWI ex U.S.
15	Fixed Income	Met West Total Return Bonds	5.7%	5.2%	Bloomberg Aggregate
16	Capital Preservation	MetLife Stable Value/GIC	0.7%	3.8%	Bloomberg Stable Value

MEKETA

Parkland Health Supplemental Plan

Plan Lineup Review

Plan Lineup Review

MEKETA

Parkland Health Supplemental Plan

Plan Lineup Review

Tiered Investment Structure



MEKETA

Parkland Health Supplemental Plan

Plan Lineup Review

US Equity Options

	Index	Active
Large	Schwab S&P 500 Index Fund (Index)	None offered
SMID	None offered	RBC Smid Cap Growth Fund (Active) AB Discovery Value Fund (Active)

→ Currently there are no passive options offered for mid cap or small cap.

MEKETA

International Equity Options

	Index	Active
Diversified	None offered	Am Funds EuroPac Growth Fund (Active)

→ Currently there is just one international equity strategy offered – an active strategy fund by American Funds.

MEKETA

Fixed Income Options

	Investment Grade Bonds	
Stable Value	MetLife Stable Value Fund (**fixed rate product**)	→ Participants have the ability to invest in a Stable Value product offered by MetLife.
Core	None offered	→ No bond index funds are offered
Core - Plus	Met West Total Return Fund (Active)	→ The one fixed income options is a core plus strategy by Met West.

MEKETA

Target Date Funds

Ticker	Fund	Classification
LIRKX	BlackRock LifePath Index Retirement	Target Date Fund
LIBKX	BlackRock LifePath Index 2025 Retirement	Target Date Fund
LINKX	BlackRock LifePath Index 2030 Retirement	Target Date Fund
LIJKX	BlackRock LifePath Index 2035 Retirement	Target Date Fund
LIKKX	BlackRock LifePath Index 2040 Retirement	Target Date Fund
LIHKX	BlackRock LifePath Index 2045 Retirement	Target Date Fund
LIPKX	BlackRock LifePath Index 2050 Retirement	Target Date Fund
LIVKX	BlackRock LifePath Index 2055 Retirement	Target Date Fund
LIZKX	BlackRock LifePath Index 2060 Retirement	Target Date Fund
TBD	2065 or later – not offered yet	Target Date Fund

→ Participants have the ability to invest in a target date funds with estimated retirement dates in five-year intervals. The further out the retirement date, the more equity exposure there is in the target date fund.

MEKETA

Overall

→ Participants have a robust (but not overwhelming) menu of investment options to choose from.

→ For those that prefer simplicity, target date funds are offered by Blackrock.

→ For those that prefer to build their own asset allocation, participants have investment options available to them that cover the majority of the investment universe.

Considerations/Recommendations

→ Plan sponsors have been criticized in the past for not offering passive options in all the major asset classes.

→ We recommend offering index products in the following areas – to complement the active strategies offered.

- US equity SMID cap
- International equity
- Investment grade bonds
- Target date 2065+

→ We also recommend considering offering an active US equity large cap to complement the existing S&P 500 Index offering.

Appendix: Additional Info on the Active Strategies

Strategy	Benchmark	Positive Characteristics
RBC SMID Growth Fund	Russell 2500 Growth Index	• Good returns, outperformed vs. benchmark over 5, and 10-year period ending Sep 30, 2024 • Top decile performance vs peers over 3 years and this strategy ranks in the top quartile over last 10 years • Below median fees for the category
AB Discovery Value Fund	Russell 2500 Value Index	• Outperformed vs. benchmark over most recent 5-year period ending Sep 30, 2024 • Top quartile performance vs peers over most recent 1-year period and strategy ranks in the top half of peer universe over 10-year period. • Below median fees for the category
Am Funds EuroPac Growth Fund	MSCI ACWI ex USA Index	• Near term performance has been below the benchmark, but strategy has added 60 bps of excess returns annually over the last 10-year period. • Ranks in the top half of peer universe over 3, 5 and 10 years. • Below median fees for the category
Met West Total Return Fund	BBg Barclays Aggregate Index	• Strategy has outperformed vs. its benchmark over the most recent YTD, 1, 5 and 10-year periods ending Sep 30, 2024 • Top quartile performance vs peers over YTD period and second quartile over the most recent 1-year period. • Below median fees for the category

Break

Discussion regarding Enterprise Risk Management

Update and Report Regarding Parkland's Cybersecurity Ongoing Initiatives

Executive Session Documents

Medical Executive Committee Credentialing Report

Possible Deliberation Regarding Supply Chain Sole Source Annual Report FY2024

Possible Deliberation Regarding Supply Chain Annual Report FY2024

Possible Deliberation Regarding Report on Federal and State Grants with Awards of $200,000 or Greater